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Abstract 
During 2015-16 Brazil experienced the largest epidemic of Zika virus ever reported. This 
arthropod-borne virus (arbovirus) has been linked to Guillain-Barré syndrome (a disorder of 
the peripheral nervous system) in adults but other neurological associations are uncertain. I 
designed and performed a retrospective clinical study in Rio de Janeiro, Brazil, investigating 
patients presenting with an acute neurological disorder and suspected recent Zika virus 
infection. I found a wider spectrum of neurological disease associated with Zika than 
reported previously, including that of the central nervous system. This has implications for 
clinical diagnostic pathways and public health measures. The study also highlighted some of 
the diagnostic challenges associated with arbovirus-associated neurological disease, and 
showed an unexpected role of chikungunya virus, another arbovirus that has spread rapidly 
through the Americas since 2013 and continues to affect millions in explosive outbreaks 
throughout the tropics. This led me to perform a systematic review of neurological disease 
associated with chikungunya virus; I summarise all described neurological manifestations, 
highlighting the wide spectrum of disease in adults and children, its importance in vertical 
transmission in neonates, comparison with Zika and dengue viruses and recent insights into 
disease mechanisms. The review will be a useful reference tool for clinicians, researchers 
and public health officials involved in managing complications of this emerging pathogen. 
Looking forward, this thesis also discusses the important unanswered questions relating to 
arbovirus-associated neurological disease, including establishing causality, defining the 
burden of disease and considerations for vaccines, and how we might approach these 
challenges. 
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Chapter 1: General Introduction 
 
1.1 Zika 
Zika virus is an arthropod-borne virus (arbovirus) first isolated in 1947 in the Zika forest, 
Uganda. Over the next five decades, the virus was of minimal clinical significance, with only 
14 documented cases of human infection.1-5 In April 2007, physicians on Yap Island, 
Federated States of Micronesia, noted an outbreak of rash, conjunctivitis, fever and 
arthralgia; Zika virus was eventually identified as the cause.6 The next reported major 
outbreak was in French Polynesia in October 2014, which preceded the explosive spread 
throughout Latin America from 2015.7 By December 2015, it had caused an estimated 0·4-
1·3 million cases in Brazil alone.8 
 
Phylogenetic analyses have shown two major distinct lineages, the African and Asian strains 
(Figure 1A); the Asian strain has been responsible for the above dissemination throughout 
the tropics (Figure 2A).9 Like the related dengue viruses, Zika is a flavivirus (genus 
Flavivirus, family Flaviviridae) that causes a fever-arthralgia-rash syndrome and is 
transmitted principally by Aedes mosquitoes and from mother to foetus. Transmission can 
also occur sexually (including male-female, male-male and female-male) and via blood 
transfusion.10 
 
The most commonly reported symptoms of acute Zika infection are a maculopapular rash, 
pruritus, fatigue, mild fever and arthralgia, following an incubation period of 3-14 days.6,7,11 
The rate of asymptomatic infection is unknown, although one study from the Yap Island 
outbreak estimated it to be approximately 80%.6 In the majority of cases, the virus does not 
cause complications and the above symptoms resolve without intervention within one week.7 
Rare cases of non-neurological complications have been reported, including transient 
myocarditis and thrombocytopenia. 12-16 
 
An apparent association between Zika virus and an increase in severe congenital disease 
and other neurological disorders, particularly Guillain-Barré syndrome (GBS) (see Table 1 
for description),17-20 prompted the World Health Organisation to declare Zika virus a public 
health emergency of international concern in February 2016.21 The association between Zika 
virus and microcephaly, part of the congenital Zika syndrome, has been the subject of much 
research over the past two years. The temporal correlation between Zika outbreaks and 
increased rates of microcephaly (defined as: “a head circumference of more than two 
standard deviations below the median for age and sex”),22 observed in Brazil and French 
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Polynesia, as well as the increased rate of microcephaly in mothers with confirmed Zika 
infection, and the detection of Zika RNA in brain tissue and amniotic fluid of microcephalic 
neonates and foetuses together provide a compelling argument in favour of a causative role 
for Zika in microcephaly.23-29 Other forms of congenital disease have been described under 
the umbrella of the congenital Zika syndrome, including arthrogryposis, cerebellar 
hypoplasia, and damage to the thalamic and corpus callosum.30-32 However, there still 
remains much to be explained regarding the association between Zika and congenital 
disease. For example, following the first wave of Zika infections in Brazil in 2015, there was 
unexplained regional variance in the incidence of ensuing microcephaly; furthermore, the 
second wave of Zika in 2016 was not associated with the expected corresponding increase 
in cases of microcephaly in any part of the country.33 The reasons underlying these 
observations will need to be sought from future research. 
 
Table 1: Summary of major acute neurological disorders. 
Neurological disorder Description 
Central nervous system 
Encephalitis Inflammation of the brain, often caused by a viral infection; can present with fever, 
confusion, seizure 
Meningitis  Inflammation of meninges (membranes surrounding brain and spinal cord); can present 
with headache, photophobia, fever, neck stiffness 
Myelitis Inflammation of spinal cord; can present with weakness, sensory loss, bowel/bladder 
dysfunction 
Acute disseminated 
encephalomyelitis 
Autoimmune demyelinating condition involving white matter of brain and spinal cord; can 
present with polyfocal neurological deficit 
Epilepsy Disturbance of brain electrical activity leading to seizures 
Migraine Primary headache disorder, often throbbing and unilateral  
Stroke Sudden onset loss of brain function secondary to ischaemia or haemorrhage 
Peripheral nervous system  
Guillain-Barré syndrome (GBS) Autoimmune insult to motor and/or sensory nerves leading to weakness +/- autonomic 
dysfunction, can lead to respiratory muscle paralysis 
Miller-Fisher syndrome GBS variant with ophthalmoplegia, ataxia and areflexia 
Myasthenia gravis Autoimmune insult to acetylcholine receptors at neuromuscular junction, leading to 
weakness 
Cranial nerve palsy Loss of function of cranial nerve(s); can present with ophthalmoplegia, diplopia, ptosis, 
facial weakness 
 
 
Neurological disease resulting from horizontally transmitted Zika virus infection is the other 
major clinical concern. Zika-associated GBS has been the most widely reported 
manifestation of such disease. GBS is an autoimmune disease where peripheral nerves and 
their spinal roots are targeted, typically following an infection. It results in weakness, 
autonomic dysfunction and can lead to death, usually from paralysis of respiratory muscles 
and ensuing dyspnoea and chest infection. Different GBS phenotypes exist; in acute 
inflammatory demyelinating polyneuropathy, the myelin sheath surrounding the neuron is 
affected, and in acute motor axonal neuropathy, the target is the axonal membrane itself.34 A 
case-control study of the French Polynesian outbreak showed an association between Zika 
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virus infection and GBS,18 although prior dengue exposure made interpretation of the 
virology results challenging because of serological cross reactivity between flaviviruses in 
current commercially available antibody assays.35 Dengue, like other flaviviruses including 
Japanese encephalitis and West Nile viruses, can also cause both peripheral and central 
nervous system (CNS) disease.36 Secondary dengue infections are associated with more 
severe dengue disease, and some have postulated that prior dengue may predispose to 
more severe Zika infection. More recently, a study from Colombia showed a strong temporal 
association between GBS and Zika virus, with viral RNA detected in samples from 17 
patients.19 Further evidence for a temporal association comes from an epidemiological 
analysis that found a close correlation between the incidences of Zika infection and GBS in 
seven Latin American countries.37 A few case reports have described Zika virus-associated 
myelitis (disease of the spinal cord),38 encephalitis (brain),39,40 meningoencephalitis,41 acute 
disseminated encephalomyelitis,42 Miller-Fisher syndrome (a GBS variant),43 and 
myasthenia gravis (neuromuscular),44 suggesting that the spectrum of neurological disease 
may be broader than initially thought. A preliminary epidemiological report from the French 
Polynesian outbreak indicated a possible increase in other neurological manifestations 
associated with Zika virus, but gave few details.45 The spectrum of neurological disease 
associated with Zika is clearly still undefined, and forms the primary research question 
addressed in Chapter 2.  
 
1.2 Chikungunya 
Chikungunya is a distinct arbovirus also identified in Africa in the 1950s that has spread to 
cause epidemics in the tropics in recent years.46 Historical accounts suggest that it may 
have caused outbreaks as early as the 18th century,47 although the virus and its disease 
were first isolated and documented respectively in 1952-3, in Tanzania.48,49 Since then, two 
lineages, namely West African and East/Central/South African (ECSA), have been shown to 
circulate in sub-Saharan Africa in a sylvatic cycle between mosquitoes and non-human 
primates.50 The first documented human outbreaks were in southern Asia during the 1960s-
70s51,52 and were caused by the Asian strain, a descendent of the ECSA strain.53 After 
decades of low transmission, an ECSA divergent re-emerged in 2004, having undergone 
two successive mutations of its envelope E1 glycoprotein.54 This new lineage, renamed the 
Indian Ocean Lineage (IOL, Figures 1B and 2B) spread from Kenya to cause explosive 
outbreaks throughout islands of the Indian Ocean, India and Southeast Asia, affecting 
millions.55 In late 2013,  the emergence of the Asian strain was reported in the Caribbean,56 
marking its first documented appearance in the Americas. It has since rapidly spread 
throughout 48 American countries and territories, causing over two million suspected cases 
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to date.57 Of note, local circulation of the ECSA strain has also recently been reported in 
Bahia state, Brazil.58 
Figure 1: Phylogenetic trees of Zika and chikungunya viruses. 
A. Zika 
 
B. Chikungunya 
 
Phylogenetic trees showing A. Zika’s relationship to other flaviviruses and divergence into the Asian and African 
strains (obtained from Musso and Gubler, Clinical Microbiology Reviews)7 and B. The divergence of chikungunya 
into four strains (obtained from Weaver, New England Journal of Medicine).46 
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Figure 2: Global spread of Zika and chikungunya viruses. 
A. Zika
 
B. Chikungunya 
 
World maps showing the global spread of Zika (obtained from Peterson et al., NEJM)59 and chikungunya 
(obtained from Weaver and Lecuit, NEJM)46 viruses. 
 
The word “chikungunya” originates from the Makonde language, spoken in Tanzania and 
Mozambique, meaning “that which bends up”;60 this refers to the debilitating arthralgia often 
occurring in the acute phase of infection, along with fever, myalgia, headache and rash. Like 
Zika and dengue viruses, it is primarily transmitted by Aedes mosquitoes and primarily 
causes a fever-arthralgia-rash syndrome; transmission can also occur vertically from mother 
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to foetus in the peri-partum period.61 Chikungunya also occasionally presents with 
neurological disease, including GBS, encephalitis and myelitis.62  
 
Unlike Zika, chikungunya is an alphavirus (genus Alphavirus, family Togaviridae). 
Classically, alphaviruses are described in two groups – the ‘old world’ viruses, including 
Sindbis, O’Nyong-Nyong and Ross River viruses, which cause a predominantly arthritic 
syndrome, and the ‘new world’ viruses, including Eastern, Western and Venezuelan equine 
encephalitis viruses, which are responsible for outbreaks of encephalitis.63 Chikungunya 
virus is now recognised as a cause of both arthritic and neurological disease throughout the 
tropics.  
 
Seroprevalence studies have reported a range of asymptomatic rates of chikungunya 
infection, from 3-47%.64 In acute symptomatic infection, following an incubation period of 
approximately 3 days,65 there is an abrupt onset of fever, headache, rash, arthralgia and 
myalgia which typically last for 1-2 weeks.66 After this, seroconversion likely confers life-long 
immunity.67 As well as neurological manifestations, chikungunya virus is associated with 
complications of the cardiovascular, renal, respiratory, hepatic, gastrointestinal and adrenal 
systems, sometimes collectively referred to as “atypical features”.68-70  
 
1.3 Demonstrating causality 
As for other arboviruses, proving that Zika or chikungunya has caused neurological disease 
can be challenging.63,71 Traditionally, a causal relationship between microbe and disease 
was based on Koch’s postulates, namely72:  
1. The agent must be demonstrable in every case of the disease 
2. The agent is not present in other diseases 
3. After isolation in culture, the agent must be able to produce the disease in 
experimental animals  
4. The agent can be recovered from the experimental animal 
There are clear limitations to these in modern microbiology. For example, we know now that 
certain pathogens can cause multiple diseases, and indeed certain diseases can be caused 
by more than one pathogen (postulates 1 and 2). Furthermore, modern technologies such as 
polymerase chain reaction (PCR) assays have increased our detection rate of certain 
pathogens over isolation in culture (postulate 3). We therefore adapt these postulates today 
in studies regarding causality. Neurological disorders associated with arbovirus infection 
have an added layer of complexity, due to the different samples used for testing for the 
presence of the viruses. The strongest evidence of causality comes from demonstrating that 
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the virus is in the central nervous system (CNS), which is most often shown by detecting 
viral RNA in the cerebrospinal fluid (CSF) by PCR; alternatively, the virus may be cultured. 
In fatal cases, autopsy material may be positive by PCR. For many patients the virus has 
cleared from the CSF by the time they present; in which case the detection of CSF IgM 
antibody by ELISA is considered diagnostic. Interpretation is complicated in flavivirus 
infections because a positive Zika-IgM test can result from known cross-reactivity of 
serological tests with dengue virus.35 Because chikungunya is an alphavirus, there is no 
serological cross reactivity with the flaviviruses, making diagnosis more straightforward 
(where other alphaviruses are not circulating). It is not known for how long virus, RNA, or 
IgM remain detectable in Zika- or chikungunya-associated neurological disease, and 
whether this differs for the different neurological disorders. By analogy with similar 
arboviruses, one might expect virus to be detectable for the first few days of illness, at which 
point it is replaced by antibody, which remains for weeks to months.  
 
Both Zika and chikungunya virus infections can be diagnosed by detecting virus in the blood 
by PCR or culture, and evidence of recent infection can also come from detection of a 
positive IgM antibody. However, a positive blood test in a patient with neurological disease 
does not necessarily mean the virus cased the disease; infection may be coincidental, and 
care must be taken to exclude other possible causes. Both viruses can also be detected in 
urine, saliva, semen and milk,73-77 but the same caveats apply.  
 
A further caveat applies to Zika antibody kinetics and detection in patients presenting with 
neurological disease in areas with endemic dengue. Following a primary dengue virus 
infection, a second exposure to a different dengue serotype can trigger a secondary immune 
response, whereby an early IgG response with an undetectable IgM response can be 
seen.78 Given the structural similarity between the two flaviviruses, a primary Zika infection 
in a patient with previous dengue (in essence, a secondary flavivirus infection) could 
theoretically induce a similar pattern (although this was not observed in a recent animal 
model, where dengue-immune macaques challenged with Zika still produced an IgM 
followed by IgG response).79 The absence of a Zika-IgM response in the CSF or serum of a 
patient presenting with neurological disease might thus not necessarily indicate an absence 
of recent, potentially causative Zika infection, because the patient may have produced a 
secondary IgG response instead. Detection of CSF IgG alone is not a particularly useful tool 
to investigate a causal relationship between virus and neurological disease, given that it may 
simply reflect an infection at any point in the past, with passive diffusion of IgG from serum 
to CSF. However, the use of the CSF antibody index, which compares CSF and serum IgG 
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and albumin, is a measure of CSF-specific IgG production80 and can thus suggest a more 
causal relationship if positive. 
 
It should be stressed that the isolation of virus, presence of genetic material or detection of 
antibody help provide evidence for causality, but do not prove it. Further evidence that can 
help build up the case for causality comes from epidemiological studies, in vitro and in vivo 
models, and animal models. There are various frameworks incorporating criteria for 
causality, two of which (Bradford Hill and Shepard’s criteria) were used in an article 
examining the association between Zika virus and birth defects, which argued for a causal 
association.24 However, such criteria also have limitations. The Bradford Hill criteria, a set of 
nine criteria often regarded as the underlying basic principles of inferring causality in 
epidemiology, were proposed in 1965 – since then, science and technology have of course 
advanced considerably and helped elucidate the mechanisms linking exposure and disease, 
not known of the time the criteria were proposed. Today, there are no hard and fast criteria 
for causality, but rather a mixture of the use of the above tools and common sense scientific 
deduction is required. 
 
1.4 Co-circulation and co-infection 
Co-circulation of Zika, chikungunya and dengue viruses has been reported in much of South 
America,81 and is a potential problem in all areas of the world where Aedes mosquitoes are 
endemic. In Rio de Janeiro, the location for the study in Chapter 1, all three viruses were 
circulating during the time period of investigation (Figure 3). Aedes albopictus mosquitoes 
have the ability to deliver more than one arbovirus in their saliva, raising the possibility of 
simultaneous transmission of the viruses.82  
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Figure 3: Incidence of notified cases of Zika, chikungunya and dengue in the state of 
Rio de Janeiro, 2014-2016. 
 
Zika, chikungunya and dengue viruses were all circulating in Rio de Janeiro during the investigation period of the 
retrospective study (Chapter 1).83 
 
Furthermore, co-infection of arboviruses has rarely been detected in patients presenting with 
neurological disease.84,85 Given that all three arboviruses are known to be neurovirulent, it is 
unclear whether in these patients, their neurological disease is associated with one or more 
of their infections. Co-infection has also been reported in pregnant women,23,86 the 
significance of which for the foetus is unclear. The most common co-infection to be reported 
in all patients is with chikungunya and dengue viruses, though this may be due to the greater 
number of epidemics of these viruses so far compared to Zika. Albeit rarely, co-infection with 
all three viruses has been reported, including in patients with neurological disease.84,87 The 
differences in disease pathogenesis, presentation and severity between mono- and co-
infections are currently unknown. 
 
1.5 Scope of thesis 
The recent introduction of both Zika and chikungunya to Latin America and ensuing large-
scale epidemics brought the complications of both viruses to the attention of the world.  
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The spectrum of neurological disease caused by Zika virus was, and still remains, a 
significant void in our understanding of this emerging pathogen. Therefore, my aim was to 
characterise this spectrum by investigating cases from the 2015-2016 Zika epidemic in Rio 
de Janeiro, Brazil, which is described in Chapter 2. As well as delineating clinical features of 
Zika-associated neurological disease, the results showed an unexpected role of 
chikungunya virus, which was not well-characterised in Latin America at the time. Although 
chikungunya-associated neurological disease has been reported far more frequently and for 
longer than Zika-associated disease, there is a clear lack of consensus and understanding 
of the conditions amongst clinicians, researchers and in the literature. This led me to perform 
a systematic review of all neurological disease associated with chikungunya virus globally, 
which is described in Chapter 3.  
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Chapter 2: The spectrum of neurological disease 
associated with Zika and chikungunya viruses in adults in 
Rio de Janeiro, Brazil: a case series. 
 
2.1 Introduction 
During 2015-16, Brazil experienced the largest outbreak of Zika virus ever reported and saw 
a subsequent increase in cases of Guillain-Barré syndrome (GBS). As discussed in the 
general introduction, clinical evidence for a causal association between Zika and GBS 
comes from a number of studies from French Polynesia and Latin America.18,37,88 
Furthermore, a handful of case reports describe Zika associated with other neurological 
disorders, including central nervous system and ocular disease.38-44,89 The full spectrum of 
neurological disease associated with Zika virus remains to be elucidated and will be vital 
information for the global response to this emergent pathogen. 
 
Brazil has been endemic for dengue virus for over 30 years and since 2014, has also 
experienced outbreaks of chikungunya virus. In Rio de Janeiro, where the study was 
conducted, local transmission of Zika and chikungunya viruses were first reported in January 
and November 2015, respectively. During the study, the city was experiencing outbreaks of 
all three arboviruses. Dengue virus is a well-recognised cause of neurological disease,71 
with reports from most countries where the virus circulates, including Brazil.90 Chikungunya 
virus can also present with neurological disease, although at the time of the study, there 
were few such reports from South America and its role had not been assessed.91 
 
To assess the spectrum of neurological disease associated with Zika virus, I studied adults 
in Rio de Janeiro with acute neurological syndromes following suspected Zika virus infection. 
Given their similarities and co-circulation, the cases were also investigated for chikungunya 
and dengue viruses. 
 
2.2 Methods 
I studied patients who had developed a new neurological condition associated with 
suspected Zika virus infection, whose samples had been submitted to the Flavivirus 
Reference Laboratory of the Instituto Oswaldo Cruz (Fiocruz), Rio de Janeiro. The study 
protocol was approved by the Comitê de Ética em Pesquisa do Instituto Nacional de 
Infectologia Evandro Chagas (reference 59254116.0.1001.5262). Patient-identifying data 
was anonymised. 
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2.2.1 Study population 
The study included patients admitted in 11 hospitals (appendix) in Rio de Janeiro from 1st 
November 2015 to 1st June 2016, who had presented with an acute neurological condition 
associated with a suspected Zika virus infection, as identified by fever, arthralgia or rash 
illness in the preceding three months. This time period was arbitrarily chosen to be able to 
capture as many cases as possible of arboviral-associated neurological disease, whilst at 
the same time not leaving too great a gap in time such that an association becomes less 
credible. In this evolving epidemic situation three approaches were used to identify patients: 
using the laboratory database, I retrospectively identified 29 patients who had had either 
cerebrospinal fluid (CSF) regardless of indication, or serum and/or urine in the context of 
neurological disease, sent to the laboratory for Zika virus diagnostics; additionally, clinicians 
from the study hospitals identified six further patients, whose CSF sample was not on the 
database and whose serum and/or urine request forms did not have an indication (Figure 4). 
Patients under the age of 12 months were excluded. The study itself was started at the end 
of June 2016, by which point four patients already had a positive Zika diagnosis via PCR 
performed by the reference laboratory. 
 
Figure 4: Study population of patients with neurological disease associated with 
suspected Zika virus infection. 
 
*These patients did not appear in the laboratory database search because their CSF sample was not recorded 
on the database and no clinical information was included in request forms for serum and/or urine. They were 
identified by the clinicians who had previously managed their care in the study hospitals. 
 
Clinical information was obtained from case notes and discussion with the patients’ clinicians 
and documented on standardised case report forms by a member of the study team. The 
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information obtained included demographics, past medical history, admission history, 
examination, investigations, diagnosis, and management. Investigations included brain and 
spine imaging for patients with suspected central nervous system infection, and nerve 
conduction studies with or without electromyography for those with peripheral disease. 
Nerve conduction study results were reviewed by an independent expert neurophysiologist 
to ensure consistency. The Brighton criteria were used to indicate the level of certainty for 
diagnosing GBS and similar criteria were applied for radiculitis, encephalitis, myelitis, and 
meningitis (appendix). It was determined whether patients had peripheral nervous system 
disease (GBS, radiculitis), CNS disease (encephalitis, myelitis, meningitis) or both. 
 
2.2.2 Laboratory testing 
CSF, serum, and urine samples were tested for evidence of Zika, chikungunya, and dengue 
virus infection at the Fiocruz Flavivirus Laboratory. The detection of viral RNA and/or IgM-
specific antibody in the CSF was considered as evidence of recent CNS infection as 
previously;71 IgM antibody in the serum, or RNA in the serum or urine was taken as evidence 
of systemic infection. All PCR (apart from the initial four samples that were already positive 
at the time of starting the study) and serological testing was performed by another student, 
Raquel Medialdea-Carrera. 
 
An expanded protocol based on the interim recommendations from the WHO for laboratory 
testing for Zika virus was followed:92 RNA was extracted from 140µl of CSF, serum, and 
urine samples and eluted in 50µl using the Qiamp Mini Elute Virus Spin Kit from Qiagen 
(Brazil). The CSF, serum, and urine samples were tested by qRT-PCR for detection of Zika, 
chikungunya, and dengue virus RNA as described previously (threshold cycle [Ct] cut-off 
was 38 for all three viruses).93 Controls included a negative extraction control, a negative 
water control and a positive control. For all three viruses, primers were used as previously 
(ZIKV 1086/1162c/1107-FAM; CHIKV 874/961/899-FAM; DENV1 8936/9023/8961, DENV2 
1426/1482/1454, DENV3 701/749/722, DENV4 884/953/939 [4-in-1 DENV assay]).93-95 
Samples positive for chikungunya PCR were re-tested because of the unexpected result. If 
two positive results were found, the result was deemed positive. If the second test was 
indeterminate, the sample was re-extracted and re-tested, and the result was only deemed 
positive if the subsequent test was positive. If the second test was negative, the result was 
deemed negative. Serum IgM and IgG antibodies to Zika virus NS1 antigen and serum and 
CSF IgM and IgG antibodies to chikungunya virus were measured using commercial ELISAs 
(Euroimmun, Luebeck, Germany), according to the manufacturer’s protocol.96-98 CSF IgM 
antibodies to Zika virus were measured using a recommended capture ELISA based on the 
US Centers for Disease Control and Prevention (CDC) emergency use authorization 
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protocol (CDC Fort Collins, CO, USA).99 Serum and CSF IgM and IgG antibodies to dengue 
virus were measured using commercial ELISAs (Panbio, Brazil). For serum samples with 
sufficient volume remaining, anti-ganglioside antibodies, which are associated with GBS and 
other autoimmune neuropathies, were tested by ELISA (Bühlmann-Gangliocombi, 
Schönenbuch, Switzerland) following the manufacturer's instructions.   
 
2.2.3 Statistical analysis 
The median time from illness onset to the development of neurological symptoms was 
compared for those with CNS and peripheral nervous system disease, and for those with or 
without CNS Zika virus infection, using the Wilcoxon-Mann-Whitney U-test.  
 
2.3 Results 
The study identified 35 patients with new neurological disease associated with a suspected 
Zika virus infection. Evidence for recent arbovirus infection was found in 22 (63%) of them. 
Table 2 and Figure 5 show the virological diagnosis for each patient, taking into account any 
potential serological cross-reactivity between flaviviruses.
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Table 2: Virological evidence for Zika, chikungunya and/or dengue virus infection in 22 patients presenting with acute neurological disease, 
ordered by date of admission. 
 
Patient 
Days between infection and 
sample collection 
Zika Chikungunya Dengue 
Other CSF 
investigations 
Virological Diagnosis 
CSF Serum Urine 
CSF 
PCR 
CSF 
IgM 
Serum 
PCR 
Serum 
IgM 
Urine 
PCR 
CSF 
PCR 
CSF 
IgM 
Serum 
PCR 
Serum 
IgM 
Urine 
PCR 
CSF 
PCR 
CSF 
IgM 
Serum 
PCR 
Serum 
IgM 
Urine 
PCR 
 1* 11 11 11 - + - - + - - - - - - + - + - 
Neg: MCS, HSV, VDRL, 
CRAG 
Zika-CNS +/- Dengue-CNS † 
2 25 25 25 - + - - - - - - + - - + - + - na 
Zika-CNS or Dengue-CNS or 
both, Chik-Syst 
3 4 6 4 - + + - + - - - - - - - - + - Neg: HSV Zika-CNS +/- Dengue-Syst † 
4 20 20 na + + - - na + - + - na - - - - na Neg: MCS Zika/Chik-CNS 
5 23 20 20 - + - - + - - - - - - - - - - Neg: MCS, VDRL Zika-CNS 
6 na 33 33 na na - - - na na - + - na na - + - Neg: MCS, VDRL Chik/Dengue-Syst 
7 18 18 19 - + - + - - - - - - - - - + - na Zika-CNS or Dengue-Syst or both 
8 29 29 29 - - - - - + - - - - - - - - - Neg: MCS Chik-CNS 
9 10 na na - + na na na + + na na na - - na na na Neg: HSV Zika/Chik-CNS 
10 15 15 70 - + - + + - - - - - - na - - - Neg: MCS Zika-CNS 
11 26 26 26 - - - - - + + - + + - - - - - Neg: MCS, VDRL Chik-CNS 
12 12 na 12 - - na na - + + na na - - - na na - na Chik-CNS 
13 6 9 9 - - - - - + - + + - - - - - - 
Neg: MCS, VDRL, 
CRAG, CMV/VZV/HSV 
Chik-CNS 
14 31 na na - - na na na + - na na na - - na na na na Chik-CNS 
15 7 na na - - na na na + - na na na - - na na na Neg: HSV Chik-CNS 
16 23 na 23 + + na na - + + na na - - - na na - na Zika/Chik-CNS 
17 na 71 72 na na - - + na na + - - na na - - - Pos: VDRL Zika/Chik-Syst 
18 23 na 23 - - na na + + + na na - - - na na - Neg: HSV Chik-CNS, Zika-Syst 
19 13 13 13 - - - - - + + + + - - - - + - na Chik-CNS, Dengue-Syst 
20 35 25 36 - - - - - - - + + + - - - - - na Chik-Syst 
21 72 72 72 - - - - - - - - + + - - - - - Neg: MCS, VDRL Chik-Syst 
22 66 60 60 - + - - - - - - - - - - - - - na Zika-CNS 
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Key: "+" =positive, "-" =negative, "na" =sample not available or inadequate volume; PCR=polymerase chain reaction; CSF=cerebrospinal fluid; MCS=microscopy, culture and sensitivity; 
HSV=herpes simplex virus, CMV=cytomegalovirus, VZV=varicella zoster virus, VDRL=venereal disease research laboratory (syphilis), CRAG=cryptococcal antigen, Chik=chikungunya; 
CNS=virus detected in central nervous system, Syst=virus detected systemically (i.e. outside CNS) only. Zika virus PCR primers used: 1086-1102, 1107-1137.93 See Table 3 for antibody levels 
and IgG results. *Preliminary information for this patient has previously been published. †These patients had PCR evidence of Zika virus infection, with serological evidence of dengue infection 
potentially secondary to cross-reactivity.  
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Table 3: Immunological assay values for 22 patients presenting with arboviral-
associated neurological disease, ordered by date of admission. 
 
 
Key:  
"na" =sample not available/not enough volume; "-" =negative; CSF=cerebrospinal fluid. Units and cut-off values: 
Zika CSF IgM (P/N = ratio of patient optical density to negative control value); Pos: P/N >3. Zika serum IgM and 
chikungunya IgM (ratio = patient sample/cut-off value); Pos: ratio ≥1·1. Zika IgG and Chikungunya IgG (relative 
units/ml, RU/ml as described by the manufacturer); Pos: RU/ml ≥22. Dengue IgM and IgG (Panbio Units, PU = 
ratio of patient optical density to cut-off value x10); Pos: PU >11. 
 
 
 
Patient 
Days between infection 
and sample collection 
Zika Chikungunya Dengue 
CSF Serum Urine 
CSF IgM 
(P/N) 
CSF IgG 
(RU/ml) 
Serum 
IgM 
(Ratio) 
Serum 
IgG 
(RU/ml) 
CSF IgM 
(Ratio) 
CSF IgG 
(RU/ml) 
Serum 
IgM 
(Ratio) 
Serum 
IgG 
(RU/ml) 
CSF IgM 
(PU) 
CSF IgG 
(PU) 
Serum 
IgM 
(PU) 
Serum 
IgG 
(PU) 
1 11 11 11 5·5 - - 111·5 - - - - 21·1 63·2 23·8 60·5 
2 25 25 25 35·6 - - >200 - - 1·2 - 17·7 16·0 43·6 62·7 
3 4 6 4 7·1 - - >200 - - - - - 21·8 13·7 66·2 
4 20 20 na 3·1 40·3 - >200 - - - - - 15·1 - 69·4 
5 23 20 20 27·7 - - >200 - - - - - na - 60·5 
6 na 33 33 na na - >200 na na 1·2 124·0 na na 47·7 65·0 
7 18 18 19 41·1 369·3 1·2 55·4 - - - - - 21·6 12·2 62·3 
8 29 29 29 - - - >200 - - - - - - - 57·1 
9 10 na na 8·7 155·8 na na 2·5 92·0 na na - - na na 
10 15 15 70 25·1 na 1·5 na - na - - na na - 55·2 
11 26 26 26 - - - 114·3 1·1 - 1·6 - - 32·6 - 57·7 
12 12 na 12 - - na na 3·1 75·8 na na - 23·8 na na 
13 6 9 9 - - - 40·6 - na 6·9 73·2 - na - 60·0 
14 31 na na - - na na - - na na - - na na 
15 7 na na - - na na - - na na - - na na 
16 23 na 23 3·5 67·5 na na 3·0 56·3 na na - 17·1 na na 
17 na 71 72 na na - 22·0 na na - - na na - 59·3 
18 23 na 23 - 37·2 na - 1·5 35·9 na na - 16·0 na na 
19 13 13 13 - 151·6 - >200 1·8 58·4 4·4 112·5 - 25·3 14·1 64·5 
20 35 25 36 - - - - - - 6·8 89·2 - - - 53·6 
21 72 72 72 - - - 86·4 - - 2·1 - - - - 54·3 
22 66 60 60 4·5 - - 24·6 - - - - - - - 65·7 
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Figure 5: Venn diagram for 22 patients showing virological evidence of CNS or 
systemic infection with Zika, chikungunya and/or dengue, and clinical presentation 
with CNS or peripheral nervous system disease. 
  
 
 
One can distinguish virological evidence of CNS or systemic infection (based on PCR/antibody detection in CSF 
or serum/urine, respectively) from clinical evidence of CNS or peripheral nervous system disease (based on 
clinical features). Patients in the inner darker circles have evidence of CNS +/- systemic infection with the 
respective virus. Those in the outer paler circles have evidence of only systemic infection with the respective 
virus. Note that patients 1 and 3 had confirmed Zika, +/- dengue; patients 2 and 7 had Zika or dengue or both.
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Twelve (34%) had evidence of Zika virus infection. Three (9%) with evidence of Zika virus 
infection alone presented with GBS (two patients) or encephalitis (one). Nine (26%) with 
evidence of Zika also had evidence for another arbovirus; five with chikungunya, three with 
dengue, one with both chikungunya and dengue. Three of them presented with GBS, 
including one with the facial diplegia and paraesthesia variant, and six had CNS infection, 
predominantly encephalitis and/or myelitis. Ten patients (29%) negative for Zika had 
evidence for another arboviral infection; eight with chikungunya and two with chikungunya 
and dengue. Two of these presented with GBS and eight with CNS disease. 
The remaining 13 patients (37%), with no evidence of a recent Zika, chikungunya, or dengue 
virus infection, presented with GBS (six patients) or CNS disease (seven). Their diagnoses 
are given in the appendix, but they are not considered further here. 
 
2.3.1 Clinical features 
All 22 patients with evidence of recent arbovirus infection were Brazilian nationals with no 
recent travel history, from 18 different districts of Rio de Janeiro. The median (range) age 
was 51·5 (17-84) years. The male:female ratio was 1:1. Their individual clinical features are 
summarised in Table 4 and a detailed example of a clinical case, patient 9, is described in 
the Panel.  
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Table 4: Individual clinical features of 22 patients presenting with neurological disease associated with Zika, chikungunya and/or dengue virus 
infection, ordered by date of admission. 
Patient Virological 
Diagnosis 
Systemic 
Features 
Prodrome 
Length 
(days) 
Neurological Features* CSF 
WCC 
CSF 
Protein 
Anti-
ganglioside 
Antibody 
Neurological 
Diagnosis (levels 
of certainty) 
Management Progress and Outcome 
1 (F/47) Zika-CNS +/- 
Dengue-CNS 
Rash, arthralgia, 
malaise 
WCC 8·0 
4 Confusion, dysarthria, drowsiness; paraparesis; GCS 3; CT 
head - diffuse white matter hypodensities  
10 1·11 GM1 Encephalitis (I) Mannitol ICU; intubated; patient 
rapidly deteriorated and 
died 
2 (F/59) Zika-CNS or 
Dengue-CNS 
or both, Chik-
Syst 
Fever, rash, 
arthralgia 
WCC 8·1 
7 UL and LL paraesthesia; spastic quadraparesis; extensor 
plantars; impaired UL and LL LT, PP, Vi, Pr; urinary 
retention; GCS 15; MRI spine – intramedullary signal 
abnormality involving cervical and thoracic cord; MRI brain - 
normal; NP - normal 
4 0·36 GM1, 
GD1a, 
GD1b 
Myelitis (I) IVIG; steroids 
x 2 
Developed pulmonary 
oedema on IVIG; 
responded to steroids, 
mRS 3 at 4 months 
3 (M/26) Zika-CNS +/- 
Dengue-Syst 
Fever 
 
1 Confusion; truncal, UL and LL paraesthesia and numbness; 
spastic hyperreflexic quadraparesis; T5 sensory level; LMN 
facial nerve and supranuclear gaze palsies; impaired UL and 
LL LT, PP, Vi, Pr; urinary incontinence; GCS 13; MRI brain 
and spine - signal abnormality involving cerebellar 
peduncles, medulla and intramedullary cervical cord 
100 1·12 GM1, 
GD1a, 
GD1b 
Encephalo-
myelitis (I,I) 
IVIG; steroids ICU; intubated; improved, 
mRS 1 at 4 months 
4 (M/34) Zika/Chik-
CNS 
Rash 12 UL and LL paraesthesia; mild ataxia; bilateral LMN facial 
nerve palsy; hyperreflexic LL; GCS 15; MRI brain - 
gadolinium enhancement of bilateral facial nerves; NP - 
normal 
2 0·69 - GBS variant 
(facial diplegia 
with 
paraesthesia) 
IVIG Improved, full recovery at 2 
months 
5 (F/41) Zika-CNS Fever, rash, 
malaise 
WCC 21·8 
5 LL and peri-orbital paraesthesia; normotonic areflexic 
paraparesis; impaired LL LT, PP, Vi; GCS 15; CT brain - 
normal 
0 2·07 na GBS (II) IVIG Improved (extent unknown) 
6 (F/30) Chik/Dengue-
Syst 
Fever, rash, 
malaise 
WCC 9·3 
27 LL paraesthesia; normoreflexic paraparesis; urinary 
retention; GCS 15; MRI brain and spine - normal; NP - 
normal  
0 0·21 - Myelitis (II) IVIG; steroids Improved (extent unknown) 
7 (F/66) Zika-CNS or 
Dengue-Syst 
or both 
Fever, 
arthralgia, 
malaise 
WCC 7·7 
13 UL and LL paraesthesia; flaccid areflexic quadraparesis; 
bilateral LMN facial nerve palsy; impaired UL and LL LT, PP, 
Vi; GCS 15; NP - AMSAN 
0 0·95 GD1a GBS (I) IVIG ICU; intubated; improved at 
1 week (extent unknown) 
8 (M/20) Chik-CNS Fever 
WCC 15·4 
0 R UL and LL paraesthesia and triparesis (L UL spared), 
hyperreflexic LL; impaired LL LT, PP, Vi, Pr; C6 sensory 
level; urinary retention; GCS 15; MRI spine - signal 
abnormality involving cervical and thoracic cord; MRI brain 
normal; NP - normal  
0 0·29 - Myelitis (I) Steroids x 2 Improved, mRS 2 at 3 
weeks 
9 (F/80) Zika/Chik-
CNS 
Fever, rash, 
arthralgia, 
malaise 
PLT 134 
WCC 7·5 
5 Headache, confusion; flaccid hyporeflexic quadraparesis; 
GCS 14; MRI brain and spine - signal abnormality involving 
anterior medulla, anterior cervical and thoracic cord, 
temporal lobes, amygdala, small area adjacent to temporal 
horn of L lateral ventricle, pachymeningeal enhancement 
117 1·74 na Encephalo-
myelitis (I,I) 
with subclinical 
meningitis 
IVIG ICU; developed sacral 
osteomyelitis; improved, 
mRS 4 at 2 months 
10 (M/38) Zika-CNS Fever, rash, 
malaise 
PLT 220 
WCC 14·0 
10 LL paraesthesia; flaccid areflexic quadraparesis; L LMN 
facial nerve palsy; impaired LL Pr; GCS 15 
1 1·72 - GBS (II) IVIG; 
antivirals 
ICU; intubated, ventilator-
associated pneumonia; 
improved (extent unknown) 
11 (M/76) Chik-CNS Rash, arthralgia 
PLT 254 
WCC 13·0 
0 2 seizures; confusion, dysarthria, headache, neck stiffness; 
spastic paraparesis; extensor plantars, palmomental reflex; 
80 1·45 GD1a Meningo-
encephalo-
myelitis (III,I,III) 
Antivirals; 
antibiotics 
Unknown outcome 
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LL neuropathic pain; T2-3 sensory level; urinary 
incontinence; GCS 14 
12 (M/63) Chik-CNS Fever, rash, 
arthralgia, 
malaise 
PLT 116 
WCC 6·5 
2 LL paraesthesia; flaccid areflexic paraperesis; T4 sensory 
level; urinary retention; fell with intracranial injury; GCS 15 
on admission, 12 after fall; CT brain normal, MRI brain and 
spine normal; NP - AMSAN  
0 0·92 - Myeloradiculitis 
(II) 
IVIG ICU, intubated (after fall 
and head injury); no 
improvement; mRS 5 at 2 
months 
13 (F/51) Chik-CNS Fever, 
arthralgia, 
malaise 
 
6 Confusion, 1 x seizure, drowsiness, dysarthria; GCS 3; CT 
head normal 
11 0·45 GQ1b Encephalitis (I) Antivirals Improved, full recovery at 2 
months 
14 (M/45) Chik-CNS Fever, 
arthralgia, 
malaise, 
diarrhoea 
PLT 203 
WCC 8·7 
29 UL and LL paraesthesia; flaccid areflexic quadraparesis; 
impaired UL and LL LT, PP; GCS 15 
0 0·75 na GBS (II) IVIG ICU; improved mRS 3 
15 (M/84) Chik-CNS Fever, rash, 
arthralgia, 
malaise, 
diarrhoea 
PLT 80 
WCC 16·3 
4 Confusion, impaired speech and swallow; flaccid 
hyporeflexic quadraparesis; myalgia; GCS 8; MRI brain - 
focal areas of hyperintensity likely related to 
microangiopathy; NP - inflammatory myopathy 
42 1·11 na Encephalitis (I), 
Myositis 
IVIG; 
antivirals; 
antibiotics; 
antifungals 
Ventilator-associated 
pneumonia; no 
improvement, mRS 5 at 6 
weeks 
16 (M/65) Zika/Chik-
CNS 
Fever, rash, 
arthralgia, 
malaise 
PLT 130 
WCC 9·9 
0 LL paraesthesia; flaccid areflexic paraparesis; T11 sensory 
level; impaired LL sensation LT, PP, Vi, Pr; urinary retention; 
GCS 15; MRI brain and spine normal; NP - AMSAN  
10 1·08 na Myeloradiculitis 
(I) 
IVIG; steroids No improvement at 3 
weeks 
17 (F/19) Zika/Chik-
Syst 
Rash 
PLT 537 
WCC 9·0 
41 UL and LL paraesthesia; quadraparesis, hyporeflexic LL; 
GCS 15; CT brain normal; NP - AMAN; patient 19 weeks 
pregnant at admission, foetus diagnosed with Dandy-Walker 
syndrome 
2 0·23 - GBS (II) IVIG No improvement at 3 
weeks 
18 (F/56) Chik-CNS, 
Zika-Syst 
Fever, rash, 
malaise 
PLT 340 
WCC 15·0 
4 LL paraesthesia; flaccid areflexic quadraparesis; impaired 
UL & LL LT, PP, Vi, Pr; C7 sensory level; urinary retention; 
GCS 15; MRI brain and spine normal; NP - AMSAN  
0 0·71 na Myeloradiculitis 
(II) 
IVIG; steroids No improvement, mRS 5 at 
1 month 
19 (M/62) Chik-CNS, 
Dengue-Syst 
Fever, rash 
PLT 680 
WCC 18·8 
8 LL paraesthesia; normotonic hyperreflexic paraplegia; 
extensor plantars; impaired LL Vi; T6-8 sensory level; urinary 
incontinence; GCS 15; CT brain normal, MRI brain and spine 
normal; NP - AIDP  
16 1·09 - Myeloradiculitis 
(I) 
IVIG; steroids Improved, mRS 2 at 1 
month 
20 (M/17) Chik-Syst Fever, rash 
PLT 362 
WCC 6·3 
16 L sided numbness (LL, UL, truncal); L hemiparesis; L UMN 
facial nerve palsy; headache; impaired L sided UL & LL LT, 
PP; GCS 15; MRI brain - demyelinating lesions R parietal 
lobe & thalamus consistent with ADEM 
na 0·44 na ADEM IVIG; steroids Improved, mRS 2 at 3 
weeks 
21 (F/67) Chik-Syst Fever, arthralgia 
PLT 397 
WCC 8·9 
7 Flaccid areflexic quadraparesis; dysphagia; palatal 
weakness; dyspnoea; impaired UL & LL Pr, LL Vi; GCS 15; 
CT brain normal; NP - AMSAN  
10 0·71 - GBS (I) IVIG x 2 ICU; intubated; no 
improvement, mRS 5 at 2 
weeks 
22 (F/52) Zika-CNS Fever 
PLT 412 
WCC 10·2 
0 LL and R facial numbness, impaired co-ordination; 
headache, diplopia; GCS 15; MRI brain - signal abnormality 
involving frontal and parietal lobes, pons and right cerebellar 
peduncle 
6 0·37 GD1a Encephalitis** Steroids Improved, mRS 0 at 2 
months 
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Key: Prodrome length=interval between the systemic features of disease and onset of neurological illness; Chik=chikungunya; CNS=virus detected in central nervous system, Syst=virus 
detected systemically (i.e. outside CNS) only; PLT=platelet count x109/L, WCC=white cell count (systemic x109/L, CSF /μL); L=left, R=right, LL=lower limb, UL=upper limb, CSF=cerebrospinal 
fluid, LMN=lower motor neuron, UMN=upper motor neuron, LT=light touch, PP=pinprick, Vi=vibration, Pr=proprioception, GCS=Glasgow coma scale; MRI=magnetic resonance imaging, 
CT=computed tomography, NP=neurophysiology; AMSAN=acute motor and sensory axonal neuropathy; AMAN=acute motor axonal neuropathy; AIDP= acute inflammatory demyelinating 
polyneuropathy; GBS=Guillain-Barré syndrome, ADEM=acute disseminated encephalomyelitis; IVIG=intravenous immunoglobulin; ICU=intensive care unit admission, mRS=modified Rankin 
Scale; "na" =not available. For neurological diagnoses the levels of diagnostic certainty are indicated I-III (highest to lowest), as per the Brighton and other criteria (appendix). The time post-
onset of neurological symptoms is given for outcomes, where known. *Note the different neurological features presented at different times, e.g. patient 8 initially presented with sensory 
symptoms, which progressed after two days to triparesis); **Although the GCS score was 15, the clinical features and imaging indicated focal encephalitis. 
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Panel: Clinical presentation of encephalomyelitis (with subclinical meningitis) 
associated with Zika and chikungunya virus infections (patient 9). 
An 80-year-old Brazilian female with a past medical history of hypertension, obesity and 
osteoarthritis presented with a one-day history of headache, confusion, and symmetrical 
weakness in all four limbs. Five days earlier, she had fever, rash, arthralgia and general 
malaise. There was no preceding history of respiratory or gastrointestinal infection, or recent 
vaccination, and she did not have any bowel or bladder symptoms.  
 
On examination, she had a diffuse, centrifugal, erythematous rash, with mild joint swelling of 
the knees. She was mildly confused with a Glasgow Coma Scale of 14. She had a flaccid 
tetraparesis, worse proximally (Medical Research Council grade 1 in all four limbs) than 
distally (Medical Research Council grade 3 in all four limbs). Her reflexes were present but 
depressed throughout. As far as assessment would allow, light touch, vibration, temperature 
and proprioception appeared normal. There was no sensory level apparent, or cranial nerve 
involvement.  
 
A lumbar puncture revealed a predominantly lymphocytic CSF pleocytosis of 117 
leucocytes/μl, elevated protein of 1.74 g/dL and glucose of 3.9 mmol/L. PCR for HSV 1 and 
2 was negative. She had a mild thrombocytopenia of 134 x 109/L and raised creatinine of 
160 µmol/L. An MRI scan of her brain and spine showed signal abnormality involving the 
anterior medulla, anterior cervical and thoracic cord, temporal lobes, amygdala and a small 
area adjacent to temporal horn of her left lateral ventricle, with pachymeningeal 
enhancement (Figure 6C, D, E). On the basis of the clinical and imaging findings she was 
diagnosed with encephalomyelitis (with subclinical meningitis) and admitted to the intensive 
care unit, where her upper limb power marginally improved without treatment. A course of 
intravenous immunoglobulin therapy did not have any further effect. The patient was 
discharged to a care home and despite physiotherapy was still unable to walk after seven 
months. 
Her CSF was positive by IgM ELISAs for Zika and chikungunya viruses. PCR was also 
positive for chikungunya, but not Zika. There was with no evidence of dengue virus infection.  
 
The initial symptoms of arboviral infection included fever (82% of the patients), rash (68%), 
malaise (55%) and arthralgia (50%). Data was available regarding when these initial 
symptoms resolved for 11 of 22 patients only (patients 4, 6, 12, 14, 15, 16, 17, 18. 19, 20, 
22) – of these, in four patients (12, 15, 16, 22), the neurological symptoms started during or 
the period of initial symptoms of infection, and in the other seven patients, the neurological 
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symptoms started (days) after the end of the initial symptoms of infection. Two patients had 
diarrhoea in the month preceding their neurological illness (Table 4); no patient reported a 
preceding lower respiratory tract infection or conjunctivitis. Five (patients 11, 13, 15, 16, 22) 
reported previous dengue. One (patient 22) reported prior vaccination against yellow fever. 
The median (range) time between infective symptoms and onset of neurological disease was 
6·5 (0-41) days. Patients presented with a range of neurological syndromes affecting the 
CNS, peripheral nervous system, or both, as detailed in Table 4.  
 
The seven patients with GBS all had a preceding febrile and/or rash syndrome, which was a 
median (range) 12 (5-41) days before the neurological presentation; there was no 
statistically significant difference in prodrome length between those with and without CNS 
Zika infection. The presentations for six patients were similar - typically paraesthesia (five 
patients) with a rapidly ascending symmetrical flaccid paralysis, involving all four limbs in five 
patients, or the legs only in one (patient 5). Another (patient 4) presented with a GBS variant, 
with bilateral lower motor neuron facial nerve palsies and paraesthesia in all four limbs.  
Fifteen patients presented with CNS disease, including encephalitis and/or myelitis, with or 
without involvement of the meninges or peripheral nerves. All had a febrile or rash 
syndrome, many with arthralgia and malaise. The median (range) time delay between this 
systemic illness and neurological disease was 4 (0-27) days; for these patients with CNS 
disease, there was no statistically significant difference in prodrome length between those 
with and without CNS Zika infection. 
 
The eight patients with encephalitis (with or without other CNS disease) had a median 
(range) Glasgow Coma Scale score of 13·5 (3-15); six were confused, and two had seizures. 
One patient had a supranuclear gaze palsy; two had facial weakness and four had difficulties 
with speech or swallowing. The ten patients with myelitis (with or without encephalitis) 
comprised five with paraparesis (one spastic, two flaccid, and two with normal tone), four 
with quadraparesis (two spastic, two flaccid) and one with a triparesis. Seven of these 
patients had a sensory level, six had urinary retention and three had urinary incontinence. 
Three patients with flaccid paresis had signs and symptoms compatible with transverse 
myelitis, namely a sensory level and urinary retention. However, one patient with 
encephalomyelitis with flaccid areflexic quadraparesis (patient 9) had extensive imaging 
changes in the anterior of the cord consistent with poliomyelitis-like anterior horn cell 
damage. Neurophysiological studies (see below) confirmed the involvement of lower motor 
neurons for four patients with myelitis: two of those with flaccid paraparesis, one with flaccid 
quadraparesis, and one with paraparesis and normal tone. The clinical characteristics of the 
 31 
patients with central, peripheral, and mixed nervous system disease are compared in Table 
5.  
 
Table 5: Clinical characteristics of 22 patients presenting with neurological disease 
associated with Zika, chikungunya and/or dengue virus infection. 
 n (%) or median (IQR) 
All patients  
(n=22) 
CNS disease 
(n=11) 
PNS disease 
(n=7) 
CNS & PNS 
disease (n=4) 
Age (years) 51·5 (35-64·5) 51 (28-67·5) 41 (35-55·5) 62·5 (60·5-63·5) 
Males 11 (50%) 5 (45%) 3 (43%) 3 (75%) 
Previous yellow fever vaccination (of 12 patients) 1 (8%) 1 of 4 (25%) 0 of 4 (0%) 0 (0%) 
Previous dengue (of 20 patients) 5 (25%) 4 (36%) 0 of 5 (0%) 1 of 3 (33%) 
Co-morbidity (of 20 patients) 10 (50%) 5 (45%) 2 of 6 (33%) 3 of 3 (100%) 
 Diabetes mellitus (type II) 2 (10%) 2 (18%) 0 of 6 (0%) 0 of 3 (0%) 
 Stroke 2 (10%) 0 (0%) 2 of 6 (33%) 0 of 3 (0%) 
 Hypertension  6 (30%) 3 (27%) 0 of 6 (0%) 3 of 3 (100%) 
 Hypercholesterolaemia 2 (10%) 1 (9%) 1 of 6 (17%) 0 of 3 (0%) 
 Cancer 2 (10%) 1 (9%) 0 of 6 (0%) 1 of 3 (33%) 
 Asthma 1 (5%) 1 (9%) 0 of 6 (0%) 0 of 3 (0%) 
 Cardiac disease 1 (5%) 0 (0%) 1 of 6 (17%) 0 of 3 (0%) 
 Neurological disease (Tourette’s syndrome) 1 (5%) 1 (9%) 0 of 6 (0%) 0 of 3 (0%) 
Systemic features     
 Fever 18 (82%) 9 (82%) 5 (71%) 4 (100%) 
 Rash 15 (68%) 7 (64%) 4 (57%) 4 (100%) 
 Arthralgia 11 (50%) 6 (55%) 3 (43%) 2 (50%) 
 Malaise 12 (55%) 5 (45%) 4 (57%) 3 (75%) 
 Diarrhoea 2 (9%) 1 (9%) 1 (14%) 0 (0%) 
Prodrome length (days) 5·5 (2·5-11·5) 4 (0·5-6·5) 12 (8·5-21) 3 (1·5-5) 
Neurological symptoms     
 Weakness 19 (86%) 9 (82%) 6 (86%) 4 (100%) 
 Sensory disturbance 17 (77%) 7 (64%) 6 (86%) 4 (100%) 
Neurological examination (of 21 patients)     
 Cranial nerve involvement 6 (29%) 2 of 10 (20%) 4 (57%) 0 (0%) 
 Sensory level 8 (38%) 4 of 10 (40%) 0 (0%) 4 (100%) 
 GCS<15 on admission 8 (38%) 6 of 10 (60%) 1 (14%) 1 (25%) 
 Diminished or absent reflexes  11 (52%) 2 of 10 (20%) 6 (86%) 3 (75%) 
 Brisk reflexes 6 (29%) 4 of 10 (40%) 1 (14%) 1 (25%) 
Lumbar puncture results     
 CSF white cell count (of 21 patients; cells/μL) 4 (0-11) 10·5 (4·5-70·5) 1 (0-2) 5 (0-11·5) 
 CSF protein (g/dL) 83·5 (44·25-111) 45 (36·4-111·5) 75 (70-133.2) 100 (86·8-108·3) 
Treatment     
 IVIG 17 (77%) 6 (55%) 7 (100%) 4 (100%) 
 Steroids 9 (41%) 6 (55%) 0 (0%) 3 (75%) 
Outcome     
 Responded to treatment (of 21 patients) 14 (67%) 7 of 10 (70%)  5 (71%) 2 (50%) 
 Admitted to ICU 8 (36%) 3 (27%) 4 (57%) 1 (25%) 
 Intubated 6 of 21 (29%) 2 of 10 (20%) 3 (43%) 1 (25%) 
 Died 1 (5%) 1 (9%) 0 (0%) 0 (0%) 
 
Key: CNS=central nervous system; PNS=peripheral nervous system. For certain parameters I did not have data 
for all patients; the number of patients for whom data was available is indicated in brackets. 
 
 
 32 
2.3.2 Virology and serology 
Zika virus RNA was detected in two CSF, one serum and six urine samples (from eight 
patients); Zika IgM was detected in 10 CSF and two serum samples (10 patients). 
Chikungunya virus RNA was detected in 11 CSF, six serum, and three urine samples (14 
patients); chikungunya IgM was detected in six CSF and seven serum samples (11 patients). 
Dengue virus RNA was not found; dengue IgM was found in two CSF and six serum 
samples (six patients). 
 
As expected, many patients had serum IgG against dengue virus, consistent with prior 
exposure (appendix). Of the 13 patients with no evidence of recent arbovirus infection, 
serum Zika virus IgG was detected in four. Anti-GM1, GD1a, GD1b and GQ1b antibodies 
were found in the serum of patients with both peripheral and central nervous system disease 
(Table 4). 
 
2.3.3 Investigations 
Ten out of the 22 patients had a CSF pleocytosis (≥5/µL, all showing predominantly 
lymphocytes/monocytes) and 15 had a CSF protein above 0·45 g/L. Four patients had a mild 
thrombocytopenia and seven had a peripheral leucocytosis, but none had leucopenia. 
Imaging studies are detailed in Table 4, with examples shown in Figure 6. High signal 
changes were found in the cervical (four patients) and thoracic (two) cord, brainstem (two), 
cerebellar peduncles (two) and cortex (three); demyelination of the parietal cortex and 
thalamus was reported in patient 20 and pachymeningeal enhancement in patient 9. Three 
different neurophysiological patterns were seen in patients with peripheral involvement - 
acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy 
(AMSAN) and acute inflammatory demyelinating polyneuropathy (AIDP) (Table 6). AMAN 
and AMSAN were seen in patients both with and without probable Zika virus infection; AIDP 
was seen only in one patient with CNS chikungunya virus infection. 
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Figure 6: Central nervous system (CNS) imaging abnormalities in patients with 
evidence of Zika, chikungunya and/or dengue virus infection.  
 
A: Encephalomyelitis in a patient with CNS Zika and systemic dengue infection (patient 3). Fluid attenuation 
inversion recovery [FLAIR] signal abnormality involving the middle cerebellar peduncles, more marked on the 
right (axial scan). 
B: Acute disseminated encephalomyelitis in a patient with systemic chikungunya infection (patient 20). Confluent 
areas of T2 signal abnormality suggesting neuroinflammation consistent with demyelination (coronal scan).  
C, D, E: Encephalomyelitis with subclinical meningitis in a patient with CNS Zika + chikungunya infection (patient 
9). FLAIR signal abnormality involving the medial temporal lobes, amygdala, and a small area of abnormality 
adjacent to the temporal horn of the left lateral ventricle (C, axial scan). High signal intensity on T2-weighted 
images in the anterior medulla, and anterior cervical and thoracic cord (D and E, sagittal scans). 
F, G, H: Myelitis in a patient with CNS Zika + dengue and systemic chikungunya infection (patient 2). Extensive 
intramedullary signal abnormality of the cervical cord, without evidence of contrast enhancement (F, sagittal T2-
weighted scan; G, sagittal T1-weighted scan with gadolinium; H, axial T2-weighted scan). 
I, J: Facial diplegia with paraesthesia in patient with CNS Zika + chikungunya infection (patient 4). Bilateral facial 
nerve enhancement on T2-weighted images with gadolinium (axial scan). 
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Table 6: Neurophysiology studies for patients with abnormal neurophysiology, 
compound muscle action potentials. 
 
 
Key: 
Amp=distal amplitude, DML=distal motor latency, CV=conduction velocity, abs=absent, "-"=test not 
done, red=abnormal result 
Patient number 7 12 15 16 17 18 19 21 
Neurophysiological 
diagnosis 
AMSAN AMSAN Inflammatory 
myopathy 
AMSAN AMAN AMSAN AIDP AMSAN 
Clinical diagnosis GBS Myelo-
radiculitis 
Encephalitis 
+ myelitis 
Myelo-
radiculitis 
GBS Myelo-
radiculitis 
Myelo-
radiculitis 
GBS 
Right/Left R L R L R L R L R L R L R L R L 
MOTOR 
MEDIAN Amp  2.8 7.1 4.2 3.6 Data 
unavailable 
7.4 11.1 15.2 15 2.5 3.4 7.18 9.2 abs 0.8 
DML 5.3 0.9 3.5 3.8 3.8 3.7 3.3 3.2 4 2.8 4.9 4.5 abs 5 
CV 38.2 44.8 47 - 53.8 55.9 57.7 51.6 52.4 50.1 46.4 49 abs 44 
ULNAR Amp 4.4 - 3.7 3.7 8 9.7 11.1 10.5 3.5 5.1 10.9 11 abs 0.6 
DML 2.8 - 2.5 3.2 2.7 2.3 2.5 2.3 2.7 2.7 3.8 3.6 abs 2.9 
CV 47.2 - 50.8 52.6 46.7 54.1 61.9 60 59.5 63.3 57.4 51 abs 43.9 
PERONEAL Amp abs 4.3 0.5 0.7 1.3 10.6 1.9 1.4 abs abs 7.5 1.35 abs abs 
DML abs 8.3 5.9 5.8 4.8 4.7 5.2 5.6 abs abs 4.7 7.4 abs abs 
CV abs 39 43.7 47.6 36.7 37 39.8 38.8 abs abs 35.8 41.5 abs abs 
TIBIAL Amp 2 0.6 2.4 - 2.1 0.8 3 3.3 - abs 13.4 12.4 0.6 0.7 
DML 6.4 10.6 4.7 -  7.5 4.7 4.9 - abs 6 6 6.8 7.5 
CV 33 35 51.2 -  34.4 31.6 38.8 - abs 37.3 40.2 34.5 40.6 
SENSORY 
MEDIAN  Amp abs abs abs 9.1  abs - 30.7 46.3 2.2 6.2 3.0 5.2 abs abs 
Onset 
lat 
abs abs abs 2.4 abs - 2.7 2.7 2.8 2.5 3.88 3.66 abs abs 
CV abs abs abs 50.6 abs - 57 55.1 45.8 55.3 43.8 41 abs abs 
ULNAR Amp 22.3 - abs abs 7.7 11.9 29.4 31.9 11.7 3.5 2.2 5.2 abs abs 
Onset 
lat 
1.9 - abs abs 2.5 2.2 2.3 2.2 2 2.2 2.94 2.8 abs abs 
CV 56.7 - abs abs 45.6 50.5 51.7 55.6 54.5 53.6 40.8 42.6 abs abs 
SUPERFICIAL 
PERONEAL 
Amp 25.1 9 - - - - 5.7 11.6 abs - 13.9 10.7 abs abs 
Peak 
lat 
4.2 4.1 - - - - 3.2 3.5 abs - 3.3 2.7 abs abs 
CV 48.4 43.7 - - - - 61.9 56.5 abs - 36.4 43.2 abs abs 
SURAL Amp - - abs 1 7.5 3.3 - - abs - 8 12.2 - - 
Peak 
lat 
- - abs 2.2 5.8 3.3 - - abs - 4.4 3.5 - - 
CV - - abs 63.3 27.4 42.8 - - abs - 31.5 39.3 - - 
 35 
2.3.4 Outcome 
Eight (36%; four with confirmed Zika) of the 22 patients required admission to an intensive 
care unit; six (27%) needed intubation (including half the patients with GBS). Ten patients 
were treated with IgG intravenous immunoglobulin (IVIG), two with corticosteroids, and 
seven with both; four with encephalitis received aciclovir as presumptive treatment for 
herpes simplex virus encephalitis. Of those treated with IVIG, fourteen had a documented 
start date of their IVIG course and of these, four (patients 5, 6, 7 and 10) had their 
serological testing done one day after commencing (the other ten had their serological tests 
taken before IVIG was commenced). Four patients developed hospital acquired infections, 
including ventilator-associated pneumonia and sacral osteomyelitis secondary to immobility. 
Fourteen (of 21 with outcome data, 67%; six with confirmed Zika) patients improved; one 
with evidence of Zika +/- dengue infection of the CNS deteriorated rapidly and died.  
 
2.4 Discussion 
With 84 countries or territories now affected by Zika virus,100 increasing reports of associated 
neurological disease other than GBS,38-41,43,44 and growing concern about coinfections with 
other arboviruses,84 there is an urgent need to determine the full spectrum of Zika’s 
neurological complications and its relationship with other arboviruses. In this study, which 
begins to address these questions, over half of the patients with Zika virus infection had 
presentations other than GBS, suggesting that these complications may be more important 
than recognised previously. Patients had involvement of the meninges, brain parenchyma, 
spinal cord, and peripheral nerves in various combinations, as evidenced by the clinical 
features, imaging and neurophysiological findings, and as has been described for other 
flaviviruses.36  
 
Four patients with evidence of Zika virus infection also had CNS infection with chikungunya 
virus. Ten further patients negative for Zika tested positive for chikungunya. In South 
America, reports of neurological disease associated with chikungunya virus are scarce, 
which may reflect a lack of awareness among clinicians about the potential to affect the 
nervous system, or the relatively recent arrival of the virus. Interestingly, in one patient who 
was pregnant at presentation, (patient 17) RNA was detected 30 days after the onset of 
neurological disease, suggesting a persistent infection or a late coincidental infection. Of 
note, this patient also had the longest prodrome period (time between first symptoms of 
infection and onset of neurological disease) of the series at 41 days, with the rest of the 
cohort presenting at less than one month after initial symptoms; it is worth considering the 
possibility that this patient’s pregnancy may have contributed to this delayed presentation. In 
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this study of patients from Rio de Janeiro, chikungunya virus was as important a cause of 
neurological disease as Zika virus. Its importance in other settings where Zika virus is 
assumed to be the cause of febrile illness, with or without neurological disease, needs to be 
assessed urgently.  
 
We are only now beginning to understand the full spectrum of neurological syndromes 
associated with both Zika and chikungunya infections. For example, patient 19 showed 
clinical signs of myeloradiculitis and had neurophysiological evidence of AIDP, which is also 
consistent with simultaneous diagnoses of both myelopathy and a form of GBS. Another 
patient (15) had an unusual combination of encephalitis, cerebral microangiopathy 
demonstrated on MRI and inflammatory myopathy based on neurophysiological studies. We 
saw evidence of extensive intramedullary myelitis in some patients, and anterior myelitis in 
another (e.g. patients 2 and 9 respectively, Figure 6); the latter is consistent with anterior 
horn cell disease seen in other flavivirus infections.101 In the French Polynesian study, 
neurophysiological investigations showed that all Zika patients with GBS had the AMAN 
subtype;18 whereas in the Colombian study, almost all had AIDP.19 This study additionally 
identified AMSAN, confirming involvement of the sensory axons in Zika virus-associated 
GBS.  
 
Antigangliosides are a subtype of glycolipid that are present in the neuronal cell membrane, 
and are involved in cell adhesion, intracellular signalling, myelin-axon interactions and 
inflammation; they can be targeted by antibodies in GBS and GBS variants, which are 
thought to result in nerve injury via the complement cascade and/or voltage gated sodium 
channels.102 In this study, one patient with AMSAN had anti-GD1a antibodies, which is more 
normally associated with AMAN. Anti-GD1a antibodies were also detected in Zika and 
chikungunya patients with central nervous system disease (Table 4). Anti-GM1, anti-GD1b, 
and anti-GQ1b antibodies were also found in patients with central nervous system disease. 
Anti-GM1 antibodies are associated with AMAN, anti-GD1b with sensory ataxic neuropathy, 
and anti-GQ1b with Miller Fisher syndrome and Bickerstaff’s brainstem encephalitis.103 The 
significance of detecting these antibodies in patients with encephalitis and myelitis is not 
certain. However, it is hoped that the results included in this series can be used in 
comparison with future studies, with the view that a higher volume of data may shed light on 
associations with certain neurological presentations and/or pathophysiological mechanisms 
of disease. 
 
Although in this study six patients had serological evidence of recent systemic dengue virus 
infection, five of them also had evidence of CNS infection with a different virus, suggesting 
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that dengue on its own was less likely to be the cause of the neurological disease (or that 
some dengue results were false positives as discussed below). One might have expected to 
see more dengue-associated neurology, given that the virus is circulating widely in Rio de 
Janeiro104 and is a well-recognised cause of neurological disease.71 Whether this in some 
way reflects the fact that it has been circulating for over 30 years in this city,90 but Zika and 
chikungunya viruses have been newly introduced, is not known. Alternatively, this may be 
due to differing neurovirulence of the three viruses.  
 
For dengue, secondary infection is a risk factor for more severe systemic dengue disease, a 
phenomenon thought to be mediated by antibody-dependent enhancement.105 Interestingly, 
in a recent in vitro study, plasma immune to dengue virus induced potent antibody-
dependent enhancement of Zika virus.106 In the 22 arbovirus-positive cases, all available 
serum samples were positive for dengue IgG antibody, indicating prior flavivirus exposure, a 
pattern also seen in 86% of tested patients in the Colombian report on GBS.19 Larger 
prospective studies are needed to investigate whether such dengue exposure is a risk factor 
for developing neurological disease after Zika virus infection.  
 
Combined infection of arboviruses has not been well described in those with neurological 
presentations. Patients in this series with evidence of dual infections, whether the 
neurological disease was caused by one arbovirus or the other, or by a combination of the 
two is unclear. The fact that so many patients had evidence of dual infection may indicate 
that combined infections are responsible for severe disease, as has been seen in other 
settings.107  
 
Flaviviruses can cause neurological disease by attacking the nervous system directly or 
indirectly via immune-mediated processes; the latter tend to occur some time after the acute 
infection, making virological diagnosis especially challenging. Detection of virus in the CSF is 
usually taken as the strongest evidence of causality, but it has often cleared by the time 
patients present, making us reliant on detection of virus systemically or demonstration of 
CSF or serum IgM antibody. Of note, in this series, the higher detection rate of Zika IgM in 
the CSF versus serum may have been due to the greater sensitivity of the CDC ELISA used 
for the CSF, as compared to the Euroimmun ELISA used in the serum (evaluation data from 
private communication, Medialdea-Carrera, R.). An elevated CSF IgG antibody index can 
also help provide causal evidence, but its use in investigating Zika-associated neurological 
disease is currently hampered by the lack of a commercially available assay specific enough 
to distinguish Zika- from dengue-IgG. For both Zika and chikungunya, whether testing urine 
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for RNA increases the window of detection compared to serum is debated. For Zika, most 
studies report prolonged shedding in urine compared to serum,108-110 however one study has 
reported the opposite.76 Data for chikungunya excretion in urine is scarce, one study of 48 
patients did not find prolonged shedding in the urine;75 a separate case report, however, 
reported a patient in whom RNA was detected in urine but not serum 30 days after 
symptoms.74 In this series, six patients (two with CNS disease) with no virus in the CSF or 
serum had virus detected in the urine (five Zika, one chikungunya). This suggests that 
testing urine in both Zika and chikungunya can be extremely useful and detect viral RNA 
after clearance from other body fluids, but given the issues surrounding chikungunya PCR in 
this study (see limitations below), future studies will have to further investigate this effect in 
chikungunya. 
 
With regard to the potential mechanism by which the associated viruses may have caused 
neurological disease in these patients, various possibilities exist. Five patients (3, 8, 11, 16, 
22) with evidence of one or more of all three viruses had a short prodromal window of 0-1 
days, and all presented with CNS disease (patient 16 also had peripheral nerve 
involvement). The short prodrome period may lend evidence to one of three potential 
mechanisms: firstly, that the virus is directly neuroinvasive, infecting cells of the nervous 
system directly; secondly, that the virus triggers a cell-mediated response (causing damage 
via molecular mimicry) before its systemic symptoms surface; and thirdly, that the virus is 
associated with a rapid, hyperacute cell-mediated response. In the first scenario, one would 
expect to detect viral RNA in the CSF, found in patients 8, 11, and 16 but not in patients 3 
and 22. In the second and third scenarios, one might expect to detect CSF antibody – IgM 
was detected in patients, 3, 11, 16 and 22 but not in patient 8. Consistent with these 
findings, it may be the case that different mechanisms exist for the different viruses and/or 
type of CNS disease. More studies are certainly needed to help further elucidate these 
mechanisms. With regard to GBS, there was a range of prodrome lengths from 5-41 days, 
consistent with the series from French Polynesia that also described a post-infectious 
temporal profile of disease.18 This argues against a direct neuroinvasive pathophysiological 
mechanism, and for autoimmune damage potentially via molecular mimicry. Two of the 
seven patients (14 and 17) did not have a positive IgM detected, but had samples missing. 
Furthermore, whether IgG may have a part to play in this process is not known. Of note, the 
series from Colombia88 reported patients with both post-infectious and para-infectious 
disease onsets; the latter of whom may have had disease due to one or more of the three 
potential pathophysiological mechanisms detailed above. 
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The results must be interpreted in the context of the study’s limitations. First, cross-reactivity 
between flaviviruses makes distinguishing Zika from dengue by serological tests 
challenging.18,35 Four patients (two of whom were positive for Zika by PCR) had elevated IgM 
antibody to both dengue and Zika, which may represent cross reactivity. Even in cases 
where CSF IgM was detected for Zika but not dengue virus, given the unknown specificity 
and sensitivity of the available flavivirus serological tests, caution must be applied. Newer 
assays in development and plaque reduction neutralization testing will help in the future. 
Differentiating infections clinically was also difficult; conjunctivitis is commonly seen in Zika7 
and not often reported for dengue or chikungunya, but I did not find conjunctivitis or any 
other clinical features that could distinguish the infections in this series. I did not look for 
West Nile virus because it had not been shown to circulate in Rio de Janeiro at the time of 
the study, but this may be important in other settings. In addition, regarding serology, there is 
a small but theoretical chance that results can be confounded by administration of IVIG 
before a serological test is taken. In these patients, this does not affect IgM serology, as the 
IVIG used was made up of polyclonal IgG only. Furthermore, only four patients (of the 14 
patients in whom the date of IVIG administration was known) had serology taken (one day) 
after IVIG was administered, and all four had IgM detected against their respective viral 
infection; their diagnoses were thus not affected. Second, the IgM ELISA assays for dengue 
(Panbio) and chikungunya (Euroimmun) have not been validated for testing in CSF. The 
assay for detecting IgM against Zika in CSF has been used as a marker of CNS replication 
in published studies,111,112 but it has only been ‘validated’ using three CSF samples.113 
Validating such assays for use with CSF samples is challenging, given that it would require 
one to assemble a series of Zika cases with neurological complications (cases without 
neurological disease would not warrant having a lumbar puncture for CSF collection). These 
cases would need to be virologically confirmed by PCR; this panel could then be used to 
determine the sensitivity and specificity of the IgM assay. Given that these cases are often 
not investigated during the window for PCR positivity because of the delayed timing of 
neurological symptoms after acute symptoms (as in several cases in this series), this makes 
formal validation difficult. Alternatively, PRNT could be used as the gold standard to confirm 
recent or past infection, but this procedure also has issues with specificity and sensitivity and 
would be difficult to interpret for rare sequelae following a common infection. Therefore, we 
are left with presuming validity of these assays in CSF, which has been used widely for 
neurological infections, but is a limitation of the study. One test that could be done to 
strengthen this presumption is to look at the IgG antibody index, as mentioned earlier, to 
confirm intrathecal antibody (regardless of class) production. Third, given the retrospective 
nature of the study, I did not have all CSF, serum and urine samples for each patient, thus 
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potentially under-diagnosing arboviral infections in the cohort; in addition, the timing of 
sample collection was not standardised. Fourth, only patients who had symptoms consistent 
with Zika infection were studied. Whether Zika virus can case neurological disease in 
patients with no febrile illness will need to be addressed in future studies. Fourth, this study 
included a relatively small number of patients, thus the spectrum of neurology and role of 
chikungunya described may be even more extensive. 
 
A detailed look at the timing of the samples and comparison between PCR and serological 
data raises some issues. Due to the retrospective nature of the study, sample timing was not 
standardised and a there was a range of time post onset of the fever-arthralgia-rash 
syndrome that samples were collected (0-72 days). In some patients, RNA was detected by 
PCR a relatively long time after fever-arthralgia-rash syndrome. For example, cases 4, 5, 8 
10, 11, 14, 16, 17, 18, 20 and 21 all have RNA detected at or over three weeks after the 
initial fever-arthralgia-rash syndrome. In some of these cases (5, 10 and 17), Zika virus RNA 
was detected in urine. As discussed, prolonged shedding of viral RNA in urine has been 
previously described in Zika virus infection,76 and so this may not come as a surprise. 
However, regarding chikungunya, cases 4, 8, 11, 14, 16 and 18 had chikungunya RNA 
detected in CSF taken more than three weeks after the initial onset of systemic features. 
Various possibilities exist to explain this. Firstly, it is unknown whether the CNS can act as a 
reservoir site for chikungunya virus, as may be the case for other viruses such as HIV,114 
which could lead to prolonged viral replication and RNA shedding. However, in these cases, 
as well as cases 17 and 20 with late detection of chikungunya RNA in serum, one would 
expect to see a positive corresponding serological response, with detection of either 
chikungunya-specific IgM or IgG antibodies. This is present in cases 11, 16, 18 and 20 but 
not in cases 4, 8, 14 and 17, whose samples were negative for IgM or IgG in the available 
samples (case 14 did not have serum available, making further interpretation difficult). 
Various explanations exist for these inconsistencies: firstly, these may represent false 
positive chikungunya PCR results. Various steps were taken to try and avoid this, including 
using negative extraction and water controls during the PCR process and using separate 
rooms for extraction and amplification; however, contamination and false positive PCR 
results are commonplace in laboratories, and this cannot be completely excluded. Another 
explanation could be that we are seeing false negative results in serological testing; the 
sensitivities of the chikungunya Euroimmun IgM and IgG assays were reported as 85% and 
88% respectively in an evaluation.98 Thirdly, although an unlikely coincidence, there remains 
a small chance that patients may have been infected with chikungunya in between the initial 
fever-arthralgia-rash syndrome (due, therefore, to another pathogen) and sample collection.  
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Does this affect the conclusions? If one were to assume the first explanation, discarding the 
chikungunya PCR results and relying on serology alone, the virological diagnoses would 
change in patients 4, 8, 14, 15 and 17. This would leave patients 2, 6, 9, 11, 12, 13, 16, 18, 
19, 20, and 21 with a positive, recent infection with chikungunya preceding their neurological 
presentation. This subset of patients includes patients with CNS, peripheral nervous system 
and mixed CNS and peripheral nervous system disease, thus not affecting the conclusion 
regarding the unexpected association of chikungunya virus with a wide range of neurological 
disease. However, conclusions regarding co-infection may be affected. Although patients 2, 
9, 16, and 18 would still (if chikungunya PCR data were discarded) show evidence of more 
than one recent infection, this would represent a lower tier in the hierarchy of evidence 
described earlier, where PCR detection or isolation of virus gives better evidence of infection 
associated with neurological disease. 
 
In summary, this work adds to the growing body of evidence arguing for a wide spectrum of 
neurological disease associated with Zika virus infection, including central nervous system 
disease. Some patients in whom a Zika virus-associated neurological disorder was 
suspected were actually infected with chikungunya virus, and many were infected with more 
than one arbovirus. This work also highlights the difficulties and limitations that accompany 
studies investigating arbovirus-associated neurological disease, especially in the 
retrospective setting. To understand fully the disease burden of Zika virus, clinicians and 
public health officials need to look beyond GBS, and also to investigate for other arboviruses 
that may cause similar neurological disease, particularly chikungunya.  
 
Despite the recognition of chikungunya-associated neurological disease in multiple 
published case reports and series globally, the disease spectrum was relatively unheard of 
by researchers and clinicians in Brazil, and indeed at the time of writing there was no 
comprehensive review in the literature. Given this and the unexpected role of chikungunya 
identified in this series, I decided to perform a systematic review of the neurological 
complications of chikungunya, in an attempt to summarise what is known of the diseases 
and provide an accessible resource to researchers and clinicians continuing to face 
epidemics of the virus. 
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Chapter 3: The neurological complications of chikungunya 
virus: a systematic review. 
 
3.1 Introduction 
Chikungunya virus is an alphavirus (genus Alphavirus, family Togaviridae) that is primarily 
transmitted to humans by Aedes mosquitoes, and occasionally from mother to child. 
Although the first outbreaks were described in the 1960s, the virus was not considered a 
major public health problem until 2004, when it caused explosive outbreaks in the tropics. 
Severe complications of chikungunya infection, including neurological disease, are being 
recognised increasingly. 
 
Dengue and Zika are also arboviruses that, like chikungunya, are transmitted by Aedes 
mosquitoes. All three arboviruses cause an initial fever-arthralgia-rash syndrome, and are 
associated with neurological complications71,115,116 Given increasing reports of co-circulation 
and co-infection of the three arboviruses in the Americas,81 the underlying viral aetiology in 
patients presenting with arbovirus-associated neurological disease is not always clear. 
Therefore, understanding the similarities and differences between chikungunya, Zika and 
dengue-associated neurological disease is of importance, and is addressed in this review. 
 
Chikungunya virus is associated with many different complications, but a disorder of the 
nervous system appears to be the most common severe. In two studies investigating 
patients with chikungunya infections requiring intensive care, a neurological disorder was the 
primary issue in 61% (11 of 18)117 and 79% (15 of 19)118 of patients with specific 
chikungunya-related complications.  
 
Unlike Zika, neurological complications of chikungunya virus have been described in many 
studies, particularly since the 2004 outbreaks. Despite this, there is a lack of awareness and 
understanding of the disease spectrum amongst clinicians and researchers globally, which 
may be due partially to a paucity of summation and appraisal of available data. Therefore, I 
performed a systematic review of the evidence for neurological disease associated with 
chikungunya virus. A well-designed review was recently published on this topical subject by 
Cerny et al.;119 the following review approaches the disease spectrum in a different manner. 
Firstly, I use a less restrictive search strategy, including articles published before 2000, 
epidemiological studies which do not necessarily report all clinical characteristics, and data 
on perinatally-acquired chikungunya infection, whereas the review by Cerny et al. had a 
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more stringent restriction process, leading to fewer but more reliably diagnosed cases 
identified. This review is also structured differently, choosing to give an overview of 
neurological complications followed by an individual assessment of each major associated 
neurological disease (the Cerny et al. review provides the overview only). Where provided, I 
present all data detailing the clinical information, investigations, management and outcome 
for all cases described in the literature. The Cerny et al. review presents this information for 
nine cases with the highest diagnostic certainty only, but goes further in other aspects, such 
as contacting authors for missing information and assessing overall patient characteristics. 
Overall, the reviews found similar patterns of disease, such as encephalitis being the most 
common neurological presentation, and peaks of incidence in elderly and infant age groups. 
Many analyses could not be compared due to differing methodology; for example, outcome 
data in Cerny et al. was presented firstly for all neurological complications and secondly for 
presumed direct viral versus autoimmune disease, whereas here it is presented per specific 
major neurological syndrome. A major difference between the reviews is that Cerny et al. 
categorised the different neurological syndromes into direct viral and autoimmune diseases, 
based on whether the therapy given was immunosuppressive or not. I did not classify cases 
as such, because it is not accurate to infer pathophysiological mechanism simply from 
treatment delivered. Of the other comparable analyses, there were no contrasting 
conclusions drawn. 
 
3.2 Methods 
I searched PubMed and Scopus for articles published up to 29th October 2017 using the 
following criteria: “chikungunya” AND (“neurolog*” OR “encephal*” OR “meningoencephalitis” 
OR “guillain-barré syndrome” OR “myelitis” OR “myelopathy” OR “stroke” OR “ocular” OR 
“optic neuritis” OR “severe” OR “unusual manifestations” OR “neonatal” OR “congenital” OR 
“perinatal” OR “fatal”) (Figure 7). There were no language restrictions. All published studies 
describing patients with neurological complications of chikungunya were considered eligible 
for inclusion, comprising case reports and series, and case-control, cohort, and cross-
sectional studies; the information from pathogenesis studies is summarised in the 
discussion. Articles that did not mention neurological complications of chikungunya were 
excluded. I identified 14 further publications by ‘hand search’ (see Figure 7) i.e. publications 
that did not appear in the systematic search but were found either through citations in other 
articles or incidentally. Data extracted included the numbers of patients with neurological 
complications, and where available, the time between systemic symptoms of infection and 
neurological disease, CSF findings, a summary of the clinical presentation, the author’s 
diagnosis, treatment given and outcome. Each study (and individual case, where possible) 
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was assigned one of three outcomes based on the data provided (as per the algorithm in 
Figure 8): A = probable; B = possible; C = interpretation difficult, disputable. Where no 
diagnosis was given, the diagnostic certainty was recorded as ‘not applicable’. The number 
of patients described per distinct neurological syndrome and aggregate data on diagnosis, 
treatment and outcome were summated. Information from pathogenesis studies identified in 
the search is discussed in Chapter 4. 
 
Figure 7: Search strategy to identify publications on neurological complications of 
chikungunya. 
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Figure 8: algorithm to classify each study on its neurological diagnostic certainty. 
 
 
*A bespoke set of results from investigations was required for each diagnosis: 
Encephalitis and myelitis: CSF WCC>5 cells/µl and/or neuroimaging compatible with 
encephalitis/myelitis 
GBS: nerve conduction studies consistent with GBS 
For encephalopathy and myelopathy, the ophthalmological disorders and cranial nerve palsies, which 
are clinical diagnoses, results from investigations were not required for outcome A. 
If there was uncertainty regarding data provided, the outcome was demoted to outcome C.  
 
3.3 Results 
 
3.3.1 Clinical findings 
Seroprevalence studies have reported a range of asymptomatic rates of chikungunya 
infection, from 3-47%.64 In acute symptomatic infection, following an incubation period of 
approximately 3 days,65 there is an abrupt onset of fever, headache, rash, arthralgia and 
myalgia which typically last for 1-2 weeks.66 After this, seroconversion likely confers life-long 
immunity.67 As well as neurological manifestations, chikungunya virus is associated with 
complications of the cardiovascular, renal, respiratory, hepatic, gastrointestinal and adrenal 
systems, sometimes collectively referred to as “atypical features”.68-70 However, a disorder of 
the nervous system appears to be the most common severe complication of chikungunya 
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infection. In two studies investigating manifestations of chikungunya in patients requiring 
intensive care, a neurological disorder was the primary issue in 61%117 and 79%118 of 
chikungunya-infected patients.  
 
In chikungunya-associated neurological disease, the clinician must be vigilant for other 
complications in the same patient, a pattern also described in dengue but rarely in Zika 
infection. Amongst 99 cases of chikungunya-associated neurological disease described in a 
study in India, 69 also had other complications involving, for example, the renal, hepatic and 
respiratory systems.69 These patients should be managed using a multi-disciplinary 
approach.  
 
3.3.2 Neurological manifestations 
The literature on neurological manifestations of chikungunya reflects that of the disease 
activity itself, with 5 publications between 1964-71, and 89 since 2005, including 27 case 
reports, 48 case series, 1 case-control study, 3 cohort studies, 1 cross-sectional study and 
14 pathogenesis studies (Figure 7); autopsy data were included in one report found.120 Table 
7 provides a summary of all cases of reported chikungunya-associated neurological disease. 
In total, 856 cases of chikungunya-associated neurological disease were found in the 
literature; 796 (93∙0%) were in adults and children infected directly via mosquito, 60 (7∙0%) 
were in neonates infected vertically from mother to child (Figure 10). Because patients were 
investigated to variable extents, I have categorised them according to the presenting clinical 
syndromes of encephalopathy, myelopathy, neuropathy, combinations of these, and neuro-
ocular disease; I then provided diagnoses, treatment and outcome where it was available. A 
limitation of this study was that I could not incorporate neurological diagnostic criteria, given 
the range of information available amongst all the cases published. However, using the 
algorithm in Figure 8, I was able to classify each study on the basis of diagnostic certainty as 
A = probable, B = possible, C = disputable and N/A (where no diagnosis was given). In the 
adult and child cases, 278 (34.9%) were classified as A, 35 (4.4%) as B, 277 (34.8%) as C, 
and 206 (25.9%) as N/A. In the perinatal cases, 20 (33.3%) were classified as A, 0 (0.0%) as 
B, 22 (36.7%) as C, 18 (30.0%) as N/A. The total values are presented in Figure 9. The 
primary reason for studies falling into category C was a lack of clinical information provided, 
as opposed to inconsistency between clinical information and given diagnosis. Although the 
qualitative aspect of the review (discussed in the sections below) has been derived from 
cases in groups A and B, it should be noted that the quantitative aspect must be interpreted 
with caution, due to the significant contribution from cases falling into group C.  
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Figure 9: Category of diagnostic certainty for all cases. 
 
Key: 
Diagnostic certainty categories: A = probable (34.8%); B = possible (4.1%); C = interpretation difficult, disputable 
(34.9%). Where no diagnosis was given, the diagnostic certainty was recorded as N/A = not applicable (26.2%). 
 
The most common clinical presentation of neurological disease associated with adult and 
child chikungunya infection was encephalopathy; it accounts for 322 (40∙5%) of the 781 
patients described. Excluding ocular disease, 474 (77∙3%) of all adult and child cases had a 
pure CNS disorder, 82 (13∙4%) had a pure peripheral nervous system disorder, and 57 
(9∙3%) had a disorder of both the central and peripheral nervous systems. Cases in which 
co-infection of chikungunya with another neurovirulent arbovirus was detected are not 
included in Table 7 but are further discussed below. 
 
  
A B C N/A
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Figure 10: Presentations of nervous system disease associated with chikungunya 
infection. 
 
   
 
Neurological disease following chikungunya virus infection was first reported during an 
outbreak in Madras, India, in 1964.121 Four cases with chikungunya confirmed serologically 
or by viral isolation were described. Two presented with a meningo-encephalitic picture, 
(“delirium or coma, and signs of meningeal irritation with nuchal rigidity and Kernig’s sign, 
sluggish pupillary reaction etc”), one with acute flaccid paralysis and elevated cerebrospinal 
fluid (CSF) protein, suggestive of Guillain-Barré syndrome, and one with transient dysarthria. 
Since then, neurological manifestations have been reported throughout the Indian ocean, 
South Asia, the Pacific islands, Southern Europe, the Caribbean and South America, ranging 
from mild behavioural disorders to severe acute syndromes of both central and peripheral 
nervous systems (Figure 11).  
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Figure 11: Global distribution of chikungunya virus and countries/territories with reported associated neurology.  
 
Key: 
 adult and child neurological disease associated with chikungunya infection 
 vertically acquired neurological disease in the neonate associated with chikungunya infection 
*unclear date of case(s), year refers to year of publication 
Data regarding global distribution of chikungunya virus acquired from Centers for Disease Control and Prevention website.122 
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Given the large spectrum of neurological disease and scarce epidemiological data, 
estimating the incidence of neurological disease amongst all systemically symptomatic 
chikungunya infections is difficult. In one study from the 2006 Indian outbreak,123 18 (4∙4%) 
of 405 suspected chikungunya cases attending the recruiting hospital over three months 
developed neurological complications; this study did not, of course, include the many people 
with uncomplicated chikungunya infection who did not seek hospital attention. An 
epidemiological study of the 2005-6 Réunion Island outbreak, found approximately 0∙3% of 
all chikungunya infections resulted in ‘atypical’ cases,68 of which 24∙1% of the adults 
presented with abnormal neurology. Thus approximately 0∙1% (1 case per 1000) of all 
chikungunya infections developed neurological disease.  
 
It has been suggested that severe complications of chikungunya infection typically arise in 
those with co-morbidities.46 The above epidemiological study describing 610 atypical cases 
of chikungunya infection showed that underlying respiratory disease, cardiac disease and 
hypertension were all independently associated with severe complications, including 
neurological disease.68 However, a study from India of 124 atypical chikungunya cases did 
not identify co-morbidity as a significant risk factor for systemic complications or fatality;69 
similarly, in a case series of chikungunya-associated GBS, six (67%) of nine cases did not 
have any co-morbidities.124 Thus, although underlying co-morbidities may play a role in 
neurological and other complications of chikungunya, they are not an indispensable 
requisite. Interestingly, age has been consistently reported as a significant risk factor for 
severe manifestations of chikungunya infection, both in the elderly (>60-65),68,69,125 and in 
infants.125  
 
Future studies will need to determine whether initially asymptomatic chikungunya infections, 
i.e. without a primary fever, arthralgia or rash syndrome, can cause neurological disease. 
Although none have been reported to date, the possibility has not yet been investigated in 
adults. In vertical transmission, a retrospective study from the Réunion Island outbreak found 
that of 38 symptomatic neonates (with combinations of fever, rash and oedema), two 
mothers had been asymptomatic (with a positive chikungunya PCR or IgM).126 However, 
mild symptoms may have been missed by the mothers due to poor recall, and whether their 
neonates developed neurological manifestations was unclear. 
 
Co-circulation of chikungunya, Zika and dengue viruses has been reported in much of South 
America,81 and is a potential problem in all areas of the world where Aedes mosquitoes are 
endemic. Aedes albopictus mosquitoes have the ability to deliver more than one arbovirus in 
their saliva, raising the possibility of simultaneous transmission of the viruses.82 Furthermore, 
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co-infection of arboviruses has been detected in patients presenting with neurological 
disease.84,85 Given that all three arboviruses are known to be neurovirulent, it is unclear 
whether in these patients, their neurological disease is associated with one or more of their 
infections. Co-infection has also been reported in pregnant women23,86, the significance of 
which for the neonate is unclear. The most common co-infection to be reported in all patients 
is with chikungunya and dengue viruses, though this may be due to the greater number 
epidemics of these viruses so far compared to Zika. Albeit rarely, co-infection with all three 
viruses has been reported, including in patients with neurological disease.84,87 The 
differences in disease pathogenesis, presentation and severity between mono- and co-
infections are currently unknown. It is clear, however, that in endemic areas, pregnant 
patients with a fever-arthralgia-rash syndrome and all patients presenting with acute 
neurological disease (regardless of previous viral symptoms) should be investigated for all 
three of chikungunya, Zika and dengue viruses. 
 
The following sections evaluate the evidence for each of the neurological syndromes that 
has been described in association with chikungunya virus infection.   
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Table 7: Reports of neurological disease associated with chikungunya virus in adults and children. 
 
Year of case(s), 
location 
No. Laboratory evidence 
for chikungunya 
PL CSF Neurological features Diagnosis Diagnostic 
certainty 
Treatment and outcome 
Encephalopathy (n=322)       
1963-4, India127 2 HI - - Unknown Encephalitis C 1 died, 1 unknown 
1962-4, Thailand,52 1 HI/isol ser - - Unknown Meningoencephalitis C Unknown 
2005-6, Mayotte128 2 PCR/IgM CSF/ser - - Unknown Meningoencephalitis C Unknown 
2005-6, Réunion118 14 PCR CSF (2/12), PCR 
serum (4/10), IgM CSF 
(11/13), IgM serum 
(12/13) 
- WCC (5/12) 
prot (8/12) 
Headaches, seizures, focal neurology, altered GCS Encephalopathy A 4 died 
2005-6, Réunion68 84 PCR/IgM CSF/ser/BL - - Unknown Encephalitis (69), 
meningoencephalitis (15) 
C 6 died 
2005-6, Réunion125 57
‡ 
PCR CSF (40/52), PCR 
serum (31/37), IgM CSF 
(21/52), IgM serum 
(32/37) 
- WCC (21/57) 
prot (37/55) 
International Encephalitis Consortium criteria used to classify patients Encephalitis (24), Non-
encephalitic CHIKV-associated 
CNS disease (33)  
A 7 died, 12 disabled, 16 recovered, 22 unknown 
2006, India129 11 IgM CSF/ser - - Headaches, altered sensorium, ataxia, rigidity, opsoclonus; abnormal brain MRI (?no.) Encephalopathy A 3 died 
2006, India69 37 Isol/PCR/IgM CSF/ser§ - - Unknown Encephalitis C 7 died 
2006, India123 11 Isol/PCR/IgM/HI 
CSF/ser (6) 
- - Unknown Encephalitis C 2 died 
2006, Réunion130  16 PCR/IgM CSF/ser - - Drowsiness, seizures, focal neurological signs; abnormal MRI brain (5) & EEG (?no.) Encephalitis (12), encephalopathy 
(4) 
A(9) B(7) 2 died, 5 disabled, 9 no neuro sequelae 
2006, India131 27 PCR CSF (4) ‖ WCC(6/20) 
prot (14/20) 
59% abnormal behaviour; 22% drowsiness, extrapyramidal; 11% seizures; abnormal MRI 
brain (1/4) 
Encephalitis A(6) B(21) 21 improved, 4 no improvement, 2 died 
2007, Italy132 1 PCR CSF & ser, HI 5d WCC, prot 83y M; confusion, drowsiness Encephalitis A Died after 3d 
2008, Singapore133 1 IgM ser 3d - 45y M; drowsiness, headache; abnormal MRI brain Encephalitis A Antimicrobials. Full recovery 
2009, Thailand134 2 IgM CSF  
HI  
3d 
0d 
WCC, prot 
WCC, prot 
27y F; drowsiness; abnormal MRI brain 
85y M; drowsiness, jerky movements; abnormal MRI brain 
Meningoencephalitis 
Meningoencephalitis 
A 
A 
Aciclovir. Full recovery at 6m 
No improvement 
2010-11, India135 4 PCR & IgM CSF, IgM ser 
PCR CSF & ser 
PCR CSF & IgM ser  
IgM CSF & ser 
4d 
- 
3d 
7d 
WCC, prot 
WCC, prot 
WCC, prot 
prot 
32y F; seizure, disorientation, neck stiffness 
50y M; headache, disorientation, drowsiness, meningism 
23y M; seizure, dysarthria, hiccups, quadriparesis, CN involvement; abnormal MRI brain; MP  
29y F; headache, neck stiffness, quadriparesis, drowsiness; abnormal MRI brain and spine 
Encephalitis 
Encephalitis 
Meningoencephalopathy 
ADEM 
A 
A 
A 
A 
Improved over 10d 
Improved over 7d 
Improved over 3w, mild weakness 
MP. Recovered at 1m, some residual weakness 
2011*, India136 1 IgM CSF & ser  10d NAD 55y M; weakness, vertigo, GCS, nystagmus, bulbar weakness; abnormal MRI brain and spine Brainstem encephalitis (ADEM) B MP. Near-complete recovery 
2011-12, 
Cambodia137 
11 PCR/Isol CSF - - <16y; unknown Meningoencephalitis C Unknown 
2012*, India138 1 IgM ser 7d WCC, prot N 32y M; seizures, stimulus sensitive myoclonus Meningoencephalitis A Anticonvulsants. Fully recovered at 3m 
2014*, India139 1 PCR & IgM CSF & ser 2d - 12y M; seizure, vomiting, altered sensorium, weakness, UL tone & tremors, unequal pupils; 
abnormal CT 
Encephalitis A Died after 6d 
2014, Tonga140 1 PCR ser, IgM CSF & ser 7d WCC N, prot 57y M; altered mental status, seizure; abnormal MRI brain & EEG  Encephalitis A IVIG, anticonvulsants. Improved 
2014, L. Antilles117 3 PCR/IgM CSF/ser - - Met Venkatesan141 criteria for encephalitis Encephalitis A Unknown 
2015, Honduras142 18 PCR ser (11)◊ - WCC, prot <12mo (11); seizures/lethargy/bulging fontanelle/irritability/hyperalgesia; abnormal MRI 
brain (5/5), abnormal EEG (7/14) 
Meningoencephalitis C 1 died, remaining unknown 
2015*, India143 3 IgM CSF/ser  - NAD 
WCC, prot N 
NAD 
19d F; tonic seizures, poor feeding  
23d M; multifocal clonic seizures   
25d F; multifocal clonic seizures, poor feeding 
Encephalopathy 
Encephalopathy 
Encephalopathy 
A 
A 
A 
Unknown 
2015*, Colombia144 1 IgM CSF/ser 4d WCC†, prot 23d M; seizures, stupor, severe thrombocytopenia; abnormal MRI brain Encephalitis A hearing, tone, motor delays at 13m 
2016*, India145 1 PCR CSF & ser - NAD 55y M; altered sensorium, GCS 12; abnormal MRI brain Mild encephalitis with a reversible 
lesion of the splenium (MERS) 
A Full recovery at 5d 
 53 
Year of case(s), 
location 
No. Laboratory evidence 
for chikungunya 
PL CSF Neurological features Diagnosis Diagnostic 
certainty 
Treatment and outcome 
2016, Brazil146 2 PCR CSF & ser, IgM ser 
PCR CSF 
6d 
4d 
WCC, prot N 
WCC, prot 
51y F; confusion, seizure, drowsiness, dysarthria 
84y M; confusion, dysarthria, dysphagia, quadriparesis; NP: myositis  
Encephalitis 
Encephalitis 
A 
A 
Aciclovir. Full recovery 
IVIG, aciclovir, antibiotics, antifungals. No improvement 
2016, India147 3 PCR ser - - Children; seizures/altered sensorium Meningoencephalitis B Recovered at 3-4d (2), died after 6h (1) 
2016*, Brazil148 2 IgM CSF/ser 4d 
6d,  
WCC, prot 
WCC, prot 
74y M; confusion, drowsiness, paraparesis; abnormal MRI brain; NP: AMSAN 
83y M; confusion, lethargy, required ventilation 
Encephalitis 
Encephalitis 
A 
A 
IVIG, plasmapheresis. Improved at 3m 
Aciclovir, IVIG. Complete recovery at 8d 
2016, Brazil149 3 IgM ser 
IgM ser 
IgM ser 
1d 
10d 
9d 
- 
WCC N, prot 
- 
<5y M; headache, seizures, GCS 3, areflexia; abnormal CT brain 
65y M; seizures, GCS 9, required ventilation; abnormal CT brain 
92y F; GCS, LL involuntary movements, required ventilation 
Not given 
Not given 
Not given 
N/A 
N/A 
N/A 
Died 23d after admission 
Aciclovir. Died 1d after admission 
Died 10d after admission  
2017*, Brazil150 1 PCR CSF & ser & urine & 
saliva 
13d WCC, prot 57y M; confusion Meningoencephalitis, anterior 
uveitis⫽ 
A Aciclovir, steroids po & top, tropicamide top. Improved 
Myelopathy (n=19)       
2006, India129 4 IgM CSF/ser - WCC, prot UR followed by paraparesis  Myelopathy A Improvement (unclear extent) 
2006, India123 5 Isol/PCR/IgM/HI 
CSF/ser (2) 
- - Unknown Myelitis C Unknown 
2006, India131 7 PCR CSF (2), isol (1) ‖ WCC(2/6), 
prot(2/6) 
Para/quadriparesis (7), UR (6); abnormal MRI spine (1) Myelopathy A 5 improved, 2 no improvement 
2015*, India151 1 IgM CSF/ser 2w WCC N, prot 18y M; quadriparesis, sensation, UR, areflexia, myositis (creatine kinase); abnormal MRI 
C1-C6 
Myelitis A MP. Slow, partial improvement 
2016, Brazil91 1 IgM ser 8d - Paraparesis, T10 sensory level Myelitis B Steroids po. Fully recovered at 2m 
2016, Brazil146 1 PCR CSF 0d NAD 20y M; paraesthesia, triparesis, hyperreflexia, C6 sensory level, UR; abnormal MRI spine; NP 
NAD 
Myelitis A MP. Partially improved 
Encephalomyelopathy (n=23)       
2005-6, Réunion68 1 PCR/IgM CSF/ser/BL - - Unknown Myelomeningoencephalitis C Unknown 
2006, India129 7 IgM CSF/ser - - Unknown Encephalomyelopathy C Unknown 
2006, India69 14 Isol/PCR/IgM CSF/ser§ - - Unknown Encephalomyelitis (11), 
encephalomyelopathy (3) 
C 5 died 
2016, Brazil146 1 PCR ser & urine, IgM 
CSF & ser  
0d WCC, prot 76y M; seizures, confusion, dysarthria, headache, neck stiffness, spastic paraparesis, T2-3 
sensory level, UI  
Encephalomyelitis A Antivirals, antibiotics. Unknown 
Myeloneuropathy (n=24)       
2006, India129 13 IgM CSF/ser   Unknown Myeloneuropathy C Unknown 
2006, India131 7 PCR CSF (1)  <5 to 
10-
20d 
WCC N (6/6), 
prot (5/6) 
Quadriparesis (6), UR (1); abnormal MRI spine (3); NP AIDP (7) Myeloneuropathy A 4 improved, 2 no improvement, 1 died 
2009, Thailand134 1 IgM CSF 2w WCC N, prot 44y F; quadriparesis, dysphonia/phagia, facial diplegia, areflexia; abnormal MRI C4-5; NP 
AMSAN  
Myeloneuropathy A IVIG. Rapid improvement, fully recovered at 6m 
2012*, India152 1 IgM ser 
 
20d WCC, prot 56y M; weakness and sensory loss; abnormal MRI spine C2-3 T5-7 Myeloradiculopathy A Improved 
2014, Dom Rep153 1 IgM & IgG ser 10d WCC, prot 47y F; L LL weakness, R LL pain, T12 sensory level; abnormal MRI T12-L1+cauda equina Myeloradiculopathy A MP. Recovered at 6m, residual pain 
2016, Brazil146 1 PCR & IgM CSF 2d WCC N, prot 63y M; paraesthesia; flaccid areflexic paraparesis; T4 sensory level; UR; NP AMSAN Myeloradiculitis B IVIG. No improvement 
Encephalomyeloneuropathy (n=24)       
2006, India129 9 IgM CSF/ser - - Unknown Encephalomyeloneuropathy C Unknown 
2006, India69 12 Isol/PCR/IgM CSF/ser - - Unknown Encephalomyeloneuritis (9), 
encephalomyeloneuropathy (3) 
C 
C 
1 died 
2008*, India120 2 IgM CSF & ser - WCC#, prot 
WCC, prot 
65y M; drowsiness, neck stiffness, weakness; abnormal MRI brain & nerve root; NP AMAN 
74y M; drowsiness, weakness; abnormal MRI brain & nerve root; NP “generalised 
sensorimotor peripheral neuropathy” 
Encephalomyeloradiculitis A 
A 
MP. No improvement 
Dexamethasone. Died; brain autopsy gross oedema, cerebellar 
haemorrhages, small foci demyelination 
2009, Singapore154 1 PCR CSF, ser, urine, skin 2d WCC N, prot 54y M; weakness, confusion, vomiting, sensory level, shock, rhabdomyolysis, UR; NP AIDP; 
EEG encephalopathy 
AIDP A*** IVIG. Full recovery 
Neuropathy (n=72)       
1963-64, India121 1 HI ser - WCCΔ, prot Quadriparesis, facial diplegia, R visual acuity  GBS B Complete slow recovery over months 
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Year of case(s), 
location 
No. Laboratory evidence 
for chikungunya 
PL CSF Neurological features Diagnosis Diagnostic 
certainty 
Treatment and outcome 
2005-6, Réunion68 4 PCR/IgM CSF/ser/BL - - Unknown GBS C Unknown 
2005-6, Réunion118 1 IgM CSF & ser - WCC N, prot 55y M; weakness, hyporeflexia, facial palsy; NP “suggestive” of GBS GBS A Moderately disabled at 6m 
2005-6, Réunion155 2 IgM CSF - WCC N, prot NP sensory-motor deficit (2) GBS C IVIG. Rapid improvement 
2006, India131 7 PCR CSF (1) ‖ prot(5/6) 
WCC N (6/6) 
Quadriparesis with AIDP (7) Peripheral neuropathy A 6 improved; 1 no improvement 
2006, Réunion156 3 IgM ser 
PCR ser 
IgM & IgG ser 
2w 
3d 
1w 
WCC N, prot 
NAD 
WCC N, prot 
51y F; quadriparesis, areflexia, facial diplegia; NP AIDP 
60y M; quadriparesis, L facial palsy, hypoaesthesia, areflexia; NP AIDP 
49y F; paraparesis, proprioceptive ataxia, areflexia, facial diplegia, dyspnoea; NP AIDP 
GBS 
GBS 
GBS 
A 
A 
A 
IVIG. Partial recovery at 1m 
IVIG. Good recovery at 1m, residual palsy 
IVIG. Good recovery at 1m, residual palsy 
2006, India129 13 IgM CSF/ser - - Unknown Neuropathy C Unknown 
2006, Réunion157 2 IgM CSF & ser 
IgM ser 
1w 
2w 
WCC N, prot 
WCC N, prot 
51y F; areflexia, facial diplegia, dyspnoea requiring ventilation; NP AIDP 
48y F; weakness, paraesthesia, areflexia, dyspnoea; NP “peripheral neuropathy, conduction 
block” 
GBS 
GBS 
A 
A 
IVIG. Good recovery at 2m  
IVIG. Good recovery  
2006, India123 2 Nil - - Unknown GBS C Unknown 
2006, India¶158 4 IgM CSF/ser - - Progressive, symmetrical, ascending quadriparesis with areflexia (4), required ventilation (1) Acute flaccid paralysis A MP. Improved: rapidly (3), by 1m (1) 
2014, L. Antilles117 6 PCR/IgM CSF/ser - - Unknown GBS C Unknown 
2014-15, Fr Poly124 9 PCR/IgM CSF/ser  - WCC N, prot Sensorimotor deficit (8), facial diplegia (1); NP mixed axonal & demyelinating (9) GBS A IVIG (9). NP returned to ~normal at 3m 
2014-15, L. 
Antilles159 
13 PCR CSF (3)/ser (3) 
IgM ser (13) 
1-
22d 
WCC N, prot Mean age 61; severe (6), autonomic dysfunction (5), required ventilation (5) AIDP (7), AMSAN (2), MFS (2), 
pharyngeal-cervical-brachial 
weakness (1), Bickerstaff’s 
brainstem encephalitis (1) 
A IVIG (12), plasma exchange (2). 2 died, 8 improved, 1 severe residual 
symptoms, 1 CIDP, 1 unknown 
2016, Brazil146 1 PCR urine, IgM ser 7d WCC, prot 67y F; flaccid areflexic quadriparesis, dysphagia, impaired sensation; NP AMSAN  GBS A IVIG. No improvement 
2016*, Colombia160 1 PCR & IgM ser - WCC N, prot 77y F; paraesthesia, bilateral hemiparesis, impaired sensation, hyporeflexia; NP AIDP  GBS A IVIG. Fully recovered at 8w 
2016, Brazil149 1 IgM ser 15d WCC, prot 51y F; quadriparesis, neck stiffness  Not given N/A Antibiotics. Died after 38h 
2016*, India161 2 IgM CSF/ser 
 
17d 
12d 
- 
- 
18y M; areflexic quadriparesis, dysphagia, dyspnoea; NP AMAN 
20y M; flaccid quadriparesis, facial & bulbar weakness; NP AIDP 
GBS 
GBS 
A 
A 
Plasmapheresis. Partial improvement 
Plasmapheresis. Partial improvement 
Ocular disease (n=78)⫽       
2006, India162 14 IgM ser 11.0d 
**  
- Visual field defect (14), visual acuity (13), pain (1), floaters (1), diplopia (1), RAPD (9), disc 
oedema (9), VII CN palsy (2), delayed VEP 
Papillitis (6), neuroretinitis (3), 
retrobulbar neuritis (3), 
demyelination optic tract (2) 
A MP 3d, steroids po 2w. 10 improved, 4 poor outcome 
2006, India163 37 IgM ser 33.2d
** 
- Primary presenting complaint visual acuity, unilateral (30), bilateral (7) Anterior uveitis (11), panuveitis 
(5), optic neuritis (4), 
lagopthalmos & VIth nerve palsy 
(3), retrobulbar neuritis (3), 
retinitis & vitritis (2), bilateral 
neuroretinitis (1), keratitis (3), 
CRAO (1), choroiditis (2), retinal 
detachment (2) 
A Visual acuity of 26 followed up: 11 improved, 12 remained stable, 3 
worsened 
2006, India129 2 IgM CSF/ser - - visual acuity Bilateral retinal haemorrhage (1), 
branch retinal artery occlusion (1)  
A Steroids intravitreal. Minimal (1)/partial (1) improvement 
2006, India164 9 IgM ser 4-
12w 
- visual acuity/pain/red eye Episcleritis (1), anterior uveitis 
(5), retinitis (3) 
A Indomethacin po; steroids, homatropine, diclofenac, timolol top; 
aciclovir iv/po, steroids po.  Recovered well (9) 
2007, India165 10 IgM ser 1-6w - visual acuity (10), pain (10), bilateral (3), visual field defects (10), disc oedema (10), RAPD 
(7), delayed VEP 
Papillitis (7), retrobulbar neuritis 
(1), perineuritis (1), neuroretinitis 
(1) 
A MP 3d, steroids po 2w. Rapid improvement (9), persistent 
RAPD/visual field/colour vision defect (4/6/2) 
2007*, India166 1 PCR & IgM ser 2w - 48y F; bilateral visual acuity, bilateral centrocaecal scotoma, retinal haemorrhage Bilateral neuroretinitis A Steroids po. Visual acuity 20/30 R 20/20 L at 2m 
2009*, India167 1 PCR aqueous humour 1w - 20y F; L visual acuity, tripod dendritic pattern of keratic precipitates Fuchs’ heterochromic iridocyclitis 
& cataract 
A Cataract surgery. Recovered well  
2010, India168 1 IgM ser 4w - 27y F; bilateral visual acuity, R RAPD, bilateral retinitis posterior pole, macular oedema, 
serous detachment 
Anterior uveitis & retinitis A Steroids po. Gradual recovery 
2011*, India169 1 PCR ser 1w - 65y M; bilateral visual acuity, neuroretinitis, cotton wool spots, retinal haemorrhages Bilateral neuroretinitis A Steroids, aciclovir po. Partial improvement 
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Year of case(s), 
location 
No. Laboratory evidence 
for chikungunya 
PL CSF Neurological features Diagnosis Diagnostic 
certainty 
Treatment and outcome 
2015*, Dom Rep170 1 IgM & IgG ser 4d NAD 47y F; bilateral visual acuity, photophobia, optic nerve head oedema, hyperpigmented scars, 
serous detachment temporal macula, represented with floaters; abnormal MRI orbits 
Panuveitis, retinal detachment A Steroids po & top, cyclopentolate top, mycophenolate. Improved 
2016*, Dom Rep171 1 IgM & IgG ser 20d - 44y F; visual acuity, floaters, keratic precipitates, anterior chamber cells, Koeppe nodules Intermediate uveitis A Steroids po & top. Rapid improvement 
Other focal neurology (n=233)       
1962-4, Thailand52 1 HI/isol CSF/ser - - Febrile convulsions Febrile convulsions N/A Unknown 
1963-64, India121 2 HI 14d 
7d 
- Limb paresis and slurring of speech 
Vocal hoarseness & nasal regurgitation 
Not given 
Not given 
N/A 
N/A 
Recovered 
1964, India121 1 
3 
HI/isol CSF/ser 
HI/isol CSF/ser 
4d 
- 
- 
NAD 
12y M; Bilateral total ophthalmoplegia, loss of accommodation reflex 
Delirium, coma, meningism, sluggish pupils, dysarthria 
CN palsy 
Not given 
A 
N/A 
Complete recovery at 1w 
Unknown 
1964, India172,173 12 PCR/IgM CSF/ser - - Seizures in infants (3), children (9); associated with fever (12), focal (2), GCS (4) Seizures N/A Died (1), residual neurological deficit (2) 
2005-06, 
Réunion155 
21 PCR/IgM CSF/ser - WCC N, prot 
(12) 
Confusion (20), headache (7), epilepsy (6), meningism (1), motor deficit (1), sensory deficit 
(2); EEG diffuse slowing (13), epileptic activity (3), NAD (2) 
Not given N/A Died (5), generally good outcome (16) 
 
2005-6, Réunion68 12 PCR/IgM CSF/ser/BL - - Seizures Seizures N/A Unknown 
2005-6, Réunion68 5 PCR/IgM CSF/ser/BL - - Unknown Stroke (2), cerebellitis (3) C Unknown 
2006, Réunion130  14 PCR/IgM CSF/ser - - Nuchal rigidity, Kernig / Brudzinski’s sign, photophobia, tense fontanelle (4) 
 
Meningeal syndrome 
Febrile seizures (10) 
N/A Mild/no neuro sequelae (1)/(3) 
Asthenia (1), no neuro sequelae (9) 
2006, India174 20 IgM ser - WCC (9), 
prot (20) 
Altered mental status (20), psychosis (6), seizures (15), CN deficit (20), hemiparesis (1), LMN 
paraparesis (3), involuntary movements (4), optic neuritis (2) 
Not clear N/A 13 gradual full improvement, 1 blind, 6 died 
2006, India175 8 PCR CSF/ser - WCC (2/5) Altered mental status, meningism, seizures, status epilepticus, aphasia Not given N/A At discharge, normal GCS (6), GCS (2) 
2006, Réunion176 25 PCR CSF (8), IgM/PCR 
ser 
- WCC (1/17) 
prot (3/17) 
Paediatric cohort: convulsion, confusion, behavioural disorders, meningism; abnormal MRI 
(2/8), abnormal EEG (8/10) 
Not given N/A Unknown 
2006, India129 18 IgM CSF/ser - - Unknown Encephaloneuropathy (8), 
Carpal tunnel syndrome (10) 
C 
C 
Unknown 
2007*, India177 1 IgM CSF/ser 13d WCC N, prot 45y M; asymmetric quadriparesis, dysphagia, clonus, dystonia; abnormal MRI brain ADEM A MP. Walking independently at 12d 
2007*, India178 1 IgM ser 2-3d - 15y F; sudden-onset profound L sided hearing loss, tinnitus Sensorineural hearing loss A No improvement at 1m 
2011*, India179 1 IgM ser 5d WCC, prot 26y F; spastic quadriplegia, impaired sensation, UR; abnormal MRI brain & spine ADEM A MP. Good clinical & radiological recovery 
2013*, India180 1 IgM CSF/ser 9d WCC, prot 8y M; flaccid quadriparesis, R UMN facial palsy, seizure, UR; abnormal MRI brain & spine ADEM A MP. Minimal improvement at 6m 
2014, Martinique181 1 IgM & IgG ser 2d - 62y M; isolated unilateral third nerve palsy CN palsy A Improved at 6m 
2014, L. Antilles117 2 PCR/IgM CSF/ser - - Diffuse brain ischaemia leading to brain death Not given N/A Died 
2014, Fr Poly119 1 IgM ser 6d WCC, prot 74y M; hypoesthesia, flaccid quadriplegia, dyspnoea, GCS 3, CN palsies, required ventilation; 
abnormal MRI brain, abnormal EEG, NP axonal polyneuropathy 
Bickerstaff’s brainstem 
encephalitis-MFS-GBS overlap 
A IVIG, MP. Normal mental function & residual paresis at 1.5 years 
2015, Honduras142 59 PCR ser - - Seizures Seizures N/A Unknown 
2016, India147 2 PCR ser (1), IgM ser (1) <7d - Children; hyperactivity, insomnia, aggressive behaviour, hallucinations, behaviour changes Not given N/A Recovered at 4d (1), persistent behavioural problems at 4w (1) 
2016, Brazil91 21 IgM ser - - Seizures, altered consciousness, weakness, impaired sensation, sphincter dysfunction, 
persecutory delusions, suicidal/aggressive behaviour, insomnia, headache 
Not given N/A Unknown 
2016, Brazil146 1 PCR ser & urine, IgM ser 16d prot N 17y M; L hemiparesis & numbness, facial palsy, impaired sensation; abnormal MRI brain ADEM A MP. Improved 
2017*, India182 1 IgM ser 10d - 5y F; bilateral ophthalmoplegia, blurring of vision Bilateral ophthalmoplegia A Steroids po. Unknown 
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Key: 
/ = “or”; e.g. IgM CSF/ser = not specified whether IgM detected in CSF or serum; PL = prodrome length (time between initial infection and onset of neurology); “-“ = data 
unavailable; PCR = polymerase chain reaction; IgM = immunoglobulin M; Isol = viral isolation; HI = haemoagglutination-inhibition; CSF = cerebrospinal fluid; Ser = serum; BL = 
bullous lesions; d = days; w = weeks; WCC = white cell count ( = >5cells/µl); Prot = protein ( = >0.4g/L adults, >1.5g/L neonates); N = normal; NAD = no abnormality 
detected; F = female; M = male; L/R = left/right; UL/LL = upper/lower limb; UMN/LMN = upper/lower motor neuron; CN = cranial nerve; UR/I  = urinary retention/incontinence; 
AMAN = acute motor axonal neuropathy; AMSAN = acute motor and sensory axonal neuropathy; AIDP = acute inflammatory demyelinating polyneuropathy; RAPD = relative 
afferent papillary defect; VEP = visual evoked potential; EEG = electroencephalogram; GBS = Guillain-Barré syndrome; MFS = Miller Fisher syndrome; CRAO = central retinal 
artery occlusion; MP = methylprednisolone; CIDP = chronic inflammatory demyelinating polyneuropathy; Diagnostic certainty: A = probable, B = possible, C = disputable, N/A = 
not applicable; Dom Rep = Dominican Republic; Fr Poly = French Polynesia; L. Antilles = Lesser Antilles 
 
Footnotes: 
* date of article submission, date of case unclear; † WCC reported as “>5”, normal neonatal WCC range 0-30 cells/µl; # WCC reported as “few cells”, unclear actual number/µl; 
Δ WCC mildly elevated, 8 lymphocytes/field; ‖ range of prodrome lengths: encephalitis: <5 to 10-20d (24), >30d (3); myelopathy: <5 to 20-30d; GBS: <5 to 10-20d; § 
neurological sequelae in cases with positive DENV IgM as well as CHIKV were attributed to CHIKV; ‡ five vertically transmitted cases; ◊ seven of these patients did not have 
laboratory evidence of chikungunya infection and were not described further, their age and whether they were vertically transmitted cases was not reported; ⫽ one patient with 
both encephalitis and anterior uveitis has not been included in the ocular disease section; ¶ Andaman & Nicobar Islands; ** mean; *** the given diagnosis of “AIDP” is 
consistent with only part of the clinical phenotype, which also consists of encephalopathy 
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3.3.3 Encephalopathy and Encephalitis 
Encephalopathy, defined by the International Encephalitis Consortium as “a clinical state of 
altered mental status, manifesting as confusion, disorientation, behavioural changes or other 
cognitive impairment,”141 is one of the most common neurological presentations for arboviral 
infections. Whilst in some patients this may be due to encephalitis – i.e. brain inflammation 
associated with direct viral infection – in others it may be a non-specific manifestation of 
severe systemic disease, for example due to hypoperfusion of the brain.71,115,183 Strictly 
speaking, encephalitis is a pathological diagnosis, but for practical purposes it can be 
diagnosed in an encephalopathic patient if there is surrogate evidence of brain inflammation, 
for example from a CSF pleocytosis, brain imaging, or focal changes on 
electroencephalogram.63,71 
 
In one study from Réunion Island, where the authors were careful to accurately define 
encephalitis using the international criteria, the estimated cumulative incidence rate for 
chikungunya-associated encephalitis was 8.6 per 100,000 people during the 2005-6 
outbreak, which lead to a two-fold incidence of all encephalitis in the region.125 Twenty-four 
patients with encephalitis were reported (five of whom were neonates infected perinatally), 
presenting with altered mental status, as well as seizures and focal neurological signs in 
some. When compared to encephalopathic patients who did not meet criteria for 
encephalitis, the encephalitic patients had more severe CNS disease and required more 
intensive care support; this was despite there being no significant difference between 
chikungunya viral loads or IgM titres in the serum or CSF, which may indicate a role for 
predisposing host factors in chikungunya virus neurovirulence. Overall, the literature review 
revealed that 251 of the 322 (78∙0%) patients who presented with an isolated 
encephalopathy syndrome had a diagnosis of encephalitis, whereas 66 (20∙5%) and 2 
(0∙6%) had a diagnosis of encephalopathy and ADEM, respectively. Additionally, 
involvement of the meninges was also reported in 55 (17∙1%) cases. 
 
Symptoms of encephalitis begin between zero and thirteen days following the onset of 
systemic features of infection (see Table 7). As is the case in other arboviral encephalitides, 
a CSF pleocytosis is not always seen.130,131 Unlike encephalitis caused by other CNS 
pathogens such as herpes simplex virus and cytomegalovirus, which have characteristic 
imaging abnormalities, chikungunya encephalitis in adults and children does not appear to 
show a distinct pattern. Described abnormalities include oedema or non-specific 
haemorrhage on CT, and increased T2 +/- fluid-attenuated inversion recovery (FLAIR) signal 
(Figure 12) or restricted diffusion signal in several areas of the cerebrum on MRI.120,130,134 
Many cases do not show any imaging abnormalities at all.125,130 Although there are non-
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specific slowing of brain waves in some patients, there is no specific electroencephalogram 
pattern.130,140 
 
In the Réunion Island study, seven of the 57 patients (aged 4 days-88 years) with either 
encephalopathy or encephalitis died in hospital or shortly after discharge; of the ten adults 
followed up after three years, three had persistent neurological sequelae in the form of 
epilepsy, post-infectious dementia and cognitive disorder.125 Taking into account the attrition 
in the follow-up cohort, a range from 18-43% of patients were estimated to have neurological 
sequelae. Similarly, a paediatric series from the same outbreak reported five (31%) of 16 
children with chikungunya-associated encephalopathy or encephalitis had residual 
neurological deficit, whilst two (13%) died.130 From the literature review, of the 127 patients 
cases for whom follow-up data was reported, 62 (48∙8%) had complete or near-complete 
recovery, 25 (19∙7%) had residual neurological deficit, and 40 (31∙5%) died. 
 
3.3.4 Myelopathy and myelitis 
Chikungunya virus can cause myelopathy, symptoms of spinal cord disease, which may 
present with limb weakness, sensory changes, hyperreflexia, bowel and bladder 
disturbances, depending on the level of the lesion, and extent to which cord is involved. If 
cord inflammation is confirmed by MRI, a CSF pleocytosis, or elevated CSF IgG index, 
showing local immunoglobulin production, then it is classified as myelitis.184  
 
The incidence of spinal cord disease after chikungunya infection is not known, but it is likely 
to be less than that of encephalopathy, given that the 90 cases described in the literature 
comprise less than a third of the 322 cases of encephalopathy. Myelopathy and myelitis 
usually occur as part of more widespread neurological disease. Of the 90 patients identified, 
47 had myelopathy as part of more widespread CNS disease, with encephalopathy or 
encephalitis; for 48 there was also peripheral nervous system disease in the form or 
radiculopathy or neuropathy; just 19 patients had a pure myelopathy syndrome. Spinal cord 
disease typically presents zero days to 3 weeks after the first clinical feature of infection 
(fever, arthralgia or rash).131,146  Patients present with weakness in two, three or four limbs, 
sometimes accompanied by one or more of paraesthesia in the limbs, a sensory level, or 
urinary retention. In the literature review, of the 12 patients with a pure myelopathy where 
CSF data was provided, six (50%) had a CSF pleocytosis. Similarly, MRI abnormalities are 
variable. They may range from changes “suggestive of demyelinating pathology” to 
extensive T2/FLAIR hyperintensity from the cervicomedullary junction to the level of C6.151  
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No deaths have been reported for chikungunya-infected patients with a pure myelopathy 
syndrome; follow-up data were reported for 13 patients, 11 of whom improved, though the 
extent of this was often unclear.  
 
3.3.5 Acute disseminated encephalomyelitis (ADEM) 
Like other acute viral infections, chikungunya can trigger an acute inflammatory syndrome 
involving the brain parenchyma and spinal cord, which is thought to be an immune-mediated 
response to infection, rather than due to direct viral invasion. The diagnosis of this 
monophasic illness is usually based on finding focal or multifocal, poorly demarcated white-
matter demyelinating lesions on MRI.185,186  
 
Six cases of ADEM (5 adults, 1 child) have been described, with the disease starting 5-16 
days after the initial fever-arthralgia-rash symptoms of chikungunya infection. Patients 
presented with a variety of neurological features, including headache, drowsiness, cranial 
nerve involvement such as facial nerve palsy, vertigo, nystagmus, and bulbar weakness; 
limb weakness, sensory disturbance, and urinary retention.  MRI of the brain and/or spine 
suggested demyelinating pathology. All six were treated with intravenous 
methylprednisolone; the outcome varied between good clinical and radiological recovery179 
and permanent neurological disability with confinement to a wheelchair and long-term 
urinary catheterisation.180 
 
3.3.6 Guillain-Barré syndrome (GBS) 
Chikungunya-associated peripheral neuropathy without CNS disease has been described for 
72 patients in case reports or series, the majority of whom were described as having GBS. In 
one series of four patients with acute flaccid paralysis, no CSF or neurophysiology results 
were reported, making diagnosis difficult.158 Other causes of acute flaccid paralysis, such as 
anterior myelitis, have not yet been reported in association with chikungunya virus. 
 
Two studies from Réunion Island showed an increased incidence of GBS following a large 
outbreak of chikungunya. One from the 2014-15 outbreak reported nine patients with 
chikungunya-associated GBS, representing a four- to nine-fold increase in the island’s 
annual GBS incidence.124 The increase in the incidence of GBS following the 2006 
chikungunya virus outbreak on Réunion Island was estimated to be ~22% compared to the 
year before.157 A study from Martinique and Guadeloupe also showed an increase in 
incidence of GBS following the 2014 chikungunya virus outbreak, but to a lesser extent (two-
fold).159 
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Clinically, chikungunya-associated GBS resembles GBS associated with other infections 
such as Campylobacter jejuni, presenting with symmetrical, bilateral flaccid weakness, often 
with paraesthesia and/or cranial nerve palsy.34 The four reports in the literature detailing the 
time interval between chikungunya infection and onset of neurological features describe a 
prodrome of 3-17 days, compatible with a para- or post-infectious syndrome (Table 
7).156,157,161  
 
Unlike infections such as C. jejuni, which is associated with a more severe pure motor 
variant of GBS,187 chikungunya appears to be associated with the full range of GBS variants, 
as determined by neurophysiological studies, including disorders of motor and sensory 
axons, and myelin sheaths, sometimes in combination (see Table 7). Further investigation is 
required to determine risk factors and markers for the different GBS variants, including anti-
ganglioside antibodies. 
 
For the 36 cases where treatment was described, 28 (78%) received intravenous 
immunoglobulin, 2 (6%) intravenous immunoglobulin and plasma exchange, 4 (11%) 
intravenous methylprednisolone and 2 (6%) plasmapheresis. 40 (87%) of the 46 cases for 
whom follow-up data were available improved. In some cases this was rapid; in most it had 
occurred by 3 months. 
 
3.3.7 Ocular complications 
Although photophobia and conjunctivitis are associated with the acute phase of chikungunya 
infection,188 many later ocular complications have been described up to 12 weeks after 
infection, which may require emergency management. These include disease of the uvea, 
retina and optic nerve. As well as inflammation, other pathology has been described, 
including retinal detachment, intra-retinal haemorrhage and branch retinal artery occlusion 
(Table 7).129,163 The literature review found 78 cases of ocular complications of chikungunya 
infection. 
 
In a retrospective study from India of 37 Indian patients with acute ocular manifestations and 
IgM-confirmed chikungunya infection, uveitis was the most common diagnosis, occurring in 
16 (43%) of patients;163 forty-eight controls from the chikungunya-endemic area, selected 
from patients attending the hospital for non-acute problems including cataract and refractive 
error, were all negative for chikungunya IgM. Recovery was variable – of the 26 patients 
followed up, the visual acuity improved in 11 (42%), remained the same in 12 (46%), and 
worsened in three (12%). Overall, of the 67 patients with ocular disease identified for whom 
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follow-up data was reported, 46 (69%) recovered well, whereas 21 (31%) showed minimal or 
no improvement. 
 
Although most of the serious ocular complications occur days to weeks after the acute 
chikungunya infection, in one report five of 14 optic neuritis cases occurred simultaneously 
with the systemic disease onset.162 This suggests a more direct viral effect may be 
important, as well a post-viral immune response. 
 
Disease relapse has been reported in one report, which described bilateral uveitis and retinal 
detachment, with loss of visual acuity starting four days after symptoms of chikungunya 
infection.170 Having received a week’s course of oral and topical steroids and recovered 
within six weeks, the patient re-presented three months later with floaters and keratic 
precipitates; clinicians should be vigilant for relapse in such cases. 
 
3.3.8 Disease affecting multiple components of the nervous system 
As well as the distinct syndromes described mentioned above, chikungunya infection is 
associated with complex disease involving multiple parts of the nervous system causing, for 
example, encephalomyelopathy (23 patients identified in the literature review), 
myeloneuropathy (24) and encephalomyeloneuropathy (24). Where follow-up data was 
available, unlike in pure myelopathy, more of these patients had an unfavourable outcome 
(eight deaths, four no improvement) compared to those who improved (eight). 
 
3.3.9 Other 
A handful of other neurological disorders have been associated with chikungunya, albeit in 
smaller numbers. A study from the Réunion outbreak described 32 patients presenting with 
behavioural changes including attention disorders, irritability and memory issues.125 Other 
reports have described febrile seizures, isolated cranial nerve palsies, stroke and hearing 
loss (Table 8), and one report describes the possibility of an association with chronic fatigue 
syndrome.189 Although it is difficult to definitively associate these isolated disorders with 
chikungunya infection, the full spectrum of chikungunya-associated neurological disease 
appears to be broad.
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Table 8: List of neurological diseases associated with chikungunya virus. 
 
Described frequently Described occasionally 
Encephalopathy Seizures with or without fever  
Myelopathy Behavioural changes  
Encephalomyelopathy  Sensorineural hearing loss 
Myeloneuropathy Stroke  
Encephalomyeloneuropathy Cerebellitis 
Guillain-Barré syndrome Meningism 
Acute disseminated encephalomyelitis (ADEM) Third nerve palsy 
Neonatal hypotonia  Encephaloneuropathy 
Neuro-ocular disease (uveitis, retinitis, optic neuritis) Carpal tunnel syndrome 
 Bilateral total ophthalmoplegia 
 Mild encephalitis with a reversible lesion of the splenium (MERS) 
 Bickerstaff’s brainstem encephalitis-MFS-GBS overlap 
 
 
Figure 12: Central nervous system imaging abnormalities in patients with chikungunya infection. 
 
A – Signal abnormality involving the periventricular white matter in an 85-year-old patient with encephalitis (axial fluid attenuated 
inversion recovery)134 
B – Confluent areas of signal abnormality consistent with demyelination in an 8-year-old patient with acute disseminated 
encephalomyelitis (coronal T2)180 
C – Signal abnormality (hyperintense) involving the corpus callosum and the frontal and parietal lobes in neonate A with vertically 
acquired encephalopathy (day 6, axial diffusion weighted imaging)61 
D – Signal abnormality (hypointense) involving the frontal and parietal lobes in neonate B with vertically acquired encephalopathy 
(day 21, axial diffusion weighted imaging)61 
E – Signal abnormality at T12 in a 47-year-old patient with myeloradiculopathy (sagittal T1)153
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3.3.10 Perinatally acquired neurological disease 
Most of the evidence on chikungunya causing neonatal disease relates to transmission in 
the intrapartum period, rather than earlier in pregnancy. A wide range of severe 
manifestations has been described affecting neonates whose mothers had acute 
chikungunya infection near the time of delivery (Table 9). A case series from Colombia from 
2014-15 described eight infants who required admission to an intensive care unit after 
contracting chikungunya infection perinatally.70 All mothers and neonates were PCR and IgM 
positive for chikungunya in serum; the neonates presented with severe disease including 
meningoencephalitis, respiratory distress, sepsis, necrotising enterocolitis, myocarditis and 
pericarditis.  
 
One study from Réunion Island described 739 mothers who experienced symptoms of 
chikungunya infection during pregnancy, 39 of whom were symptomatic in the intrapartum 
period (between two days before and two days after delivery).61 Of these 39 mothers, all 
infants were asymptomatic at birth, but 19 developed acute disease a median four (range 
three-seven) days after delivery, giving a vertical transmission rate of approximately 50% for 
mothers symptomatic in the intrapartum period. The initial clinical features in the affected 
neonates included fever, distress, poor feeding, petechiae and a maculopapular rash. Nine 
cases (47%) were reported to have developed encephalopathy. CSF for all nine showed 
normal biochemistry and white cell counts, and chikungunya PCR was detected in five. MRI 
imaging data from this study, combined with a later follow-up study190 shows that among 
neonates developing encephalopathy or encephalitis after perinatally acquired chikungunya, 
severe white matter injury is well-characterised in a three-stage pattern: cytotoxic brain 
oedema (ischaemia), vasogenic oedema (reperfusion) and mass reduction 
(demyelination).61,190 
 
In addition to these severe features, hypotonia has been described in 17 neonates with 
chikungunya infection from Réunion Island126, as well as intracerebral haemorrhage 
secondary to clotting abnormalities.61,191  Interestingly, neonatal spinal cord and peripheral 
nervous system disease have not been reported.  
 
With regard to prevention of transmission, no studies have found a protective effect of 
caesarean section.61,192 The risk factors for vertical transmission are not understood, 
although in one study the viral load of chikungunya in the placentas of the 19 transmitters 
was found to be significantly higher than in 13 non-transmitters.61  Interestingly, one of the 
transmitters gave birth to dizygous twins, of whom one acquired infection but the other did 
not.  
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In addition to overt disease in some perinatally-infected neonates soon after delivery, there 
is also evidence for impacts on longer term development. In one study comparing the 
neurocognitive function at approximately two years of age for 33 children with and 135 
without perinatal chikungunya infection, significant differences in development quotients 
were found, including movement, coordination, language and sociability.190 Importantly, even 
those infected at birth without obvious clinical features of neurological disease, such as 
encephalopathy, had significantly worsened neurocognitive function than uninfected 
children. Thus, the neurological effects of vertically transmitted chikungunya may not be 
obvious at birth, emphasising the importance of follow-up of this cohort. The 12 cases with 
encephalopathy at birth showed still more severe developmental deficit, including cerebral 
palsy and microcephaly. 
 
Maternal chikungunya virus infection earlier in pregnancy does not appear to affect the 
foetus; in the above study investigating 739 mothers with chikungunya infection, 700 were 
symptomatic outside of the intrapartum period, and none of these infants developed 
symptoms of chikungunya.61  
 
Of note, in three out of seven miscarriages occurring before 22 weeks, chikungunya RNA 
was detected in amniotic fluid for all three, and placenta and foetal brain for two. However, 
no significant increase in antepartum foetal deaths was seen during the chikungunya 
outbreak as compared with previous years. Another study of 1400 mothers from Réunion 
Island193 found no effect of antepartum chikungunya infection on pregnancy outcomes. 
Together, these data would suggest that although antepartum congenital infection has been 
detected in miscarried foetuses, given the lack of epidemiological evidence for a causal 
association between infection and miscarriage, this may have been an incidental finding.  
 
Zika virus is also now known to cause devastating neurological disease in neonates, which 
is of global concern.24 Whereas chikungunya appears to be most damaging around the time 
of birth, Zika has been associated with neurological sequelae in infections at all stages of 
pregnancy.23 Another important difference is in the initial presentation of neonatal disease – 
in perinatal chikungunya infections, fever-rash and neurological symptoms are only seen at 
approximately 4 days post-partum. In the Zika congenital syndrome, the damage is done in 
utero, thus neonates can be born with clear evidence of infection, such as microcephaly. 
Despite the magnitude of outbreaks throughout the tropics, there is a paucity of data on the 
effects of dengue virus in pregnancy. A recent large retrospective study from Brazil reported 
an increased risk of preterm birth associated with dengue infection, with no difference in the 
rate of congenital malformations.194 Adverse outcomes in neonates following perinatal 
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dengue infection, such as thrombocytopenia, dengue haemorrhagic fever, and dengue 
shock syndrome, have been described in a handful of case reports and series in 
neonates;195-197 but unlike chikungunya and Zika, apart from one case of anoxic 
encephalopathy,198 neurological complications have not been reported. 
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Table 9: Reports of perinatally acquired neurological disease associated with chikungunya virus. 
 
 
 
Key: 
PP = onset of neurological disease days post-partum; Ne = neonate; M = mother; PCR = polymerase chain reaction; IgM = immunoglobulin M; CSF = cerebrospinal fluid; Ser = serum; “-“ = 
data unavailable; d = days; WCC = white cell count ( = >5cells/µl); Prot = protein ( = >0.4g adults, >1.5g neonates); N = normal; NAD = no abnormality detected; VEP = visual evoked 
potential; EEG = electroencephalogram; DIC = disseminated intravascular coagulation; Diagnostic certainty: A = probable, B = possible, N/A = not applicable; Dom Rep = Dominican Republic 
 
Footnotes: 
* At least 17 patients; unclear whether seizures and hypotonia were seen in the same or different patients; † Patient had a subarachnoid haemorrhage and optic atrophy in addition to 
encephalitis 
Year of case(s), location No. Evidence for chikungunya PP CSF Neurological features  Diagnosis Diagnostic 
certainty 
Treatment and outcome 
Perinatal encephalopathy (n=35) 
2005-6, Réunion125 5 Ne: PCR CSF  - - Fulfilled International Encephalitis Consortium criteria for 
encephalitis 
Encephalitis A Cerebral palsy & blindness (1), poor 
neurodevelopmental performance (1) 
2005-6, Mayotte128 3 Ne&M: PCR/IgM CSF/ser - - Unknown Meningoencephalitis C Unknown 
2005-6, Réunion191 4 Ne&M: PCR/IgM ser 3-7d - Seizures; EEG consistent with encephalitis Meningoencephalitis A Survived 
2010, India199 2 Ne&M: PCR ser  5d 
3d 
NAD 
NAD 
Altered sensorium, apnoeic seizures 
Apnoeic seizures, lethargy 
Encephalopathy 
Encephalopathy 
A 
A 
Spastic diplegia, epilepsy, mental 
retardation 
tone, cerebral palsy, vision, mental 
retardation 
2014-15, Colombia70 2 Ne&M: PCR/IgM ser - - Unknown Meningoencephalitis C Unknown 
2014-15, El Salvador, 
Colombia & Dom Rep192 
12 Ne: PCR/IgM ser/CSF (10) - - Unknown Meningoencephalitis C Unknown 
2015, Brazil200 1 Ne: PCR CSF, ser, urine, saliva 6d WCC N, 
prot 
Seizures; abnormal MRI brain Encephalitis A Anticonvulsants. Improved at 17d 
2015, Honduras142 3 PCR ser  - WCC , 
prot  
Unknown Meningoencephalitis C Unknown 
2016*, India201 2 Ne&M: IgM ser 5d - Dizygotic twins; both had seizures, required ventilation, 
thrombocytopenia; abnormal MRI brain 
Encephalopathy A Both improved and discharged at 24d 
2016, Brazil202 1 Ne: PCR CSF; M: IgM ser 4 WCC , 
prot  
Prostration, lethargy, seizures, required ventilation, 
thrombocytopenia; abnormal MRI brain & EEG 
Encephalitis A Cerebral palsy, microcephaly, epilepsy at 1 
year 
Perinatal brain haemorrhage (n=7) 
2005-6, Réunion61 2 Ne&M: PCR/IgM CSF/ser - - DIC, transient scattered parenchymal petechiae (1), cerebellar 
haematoma (1)  
Haemorrhage A Unknown 
2005-6, Réunion126 2 Ne&M: PCR/IgM CSF/ser - - Unknown Haemorrhage C Unknown 
2005-6, Réunion191 1 Ne&M: PCR & IgM ser  3-7d - Severe thrombocytopenia, cerebral haemorrhage  Haemorrhage A Survived 
2015, Brazil203 1 Nil 4d NAD Intraventricular bleed (cranial US), lethargy  Haemorrhage A Improved, discharged after 17d 
2012, India204 1 M: IgM ser; Ne: NAD 3 NAD Lethargic, severe thrombocytopenia, focal bleeds basal ganglia & 
subcortical areas 
Haemorrhage A Fully recovered 
Perinatal other (n=18) 
2005-6, Réunion126 17* Ne&M: PCR/IgM CSF/ser - - Seizures (6); hypotonia (17) Seizures / hypotonia N/A Unknown 
2005-6, Mayotte128 1 Ne&M: PCR/IgM CSF/ser - - Hypotonia Hypotonia N/A Unknown 
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3.3.11 Management 
There are currently no specific antiviral agents or vaccines for chikungunya virus.205 Various 
in vitro compounds active against chikungunya virus have been reported, including both 
direct-acting and host-targeting antivirals; however, most of these compounds are yet to find 
their way into in vivo models and clinical trials.206 Two of the few that have been tested 
clinically, chloroquine and ribavirin, are already widely used in the treatment of other 
diseases and have a known safety profile. However, chloroquine was found not to have any 
benefit for arthritic chikungunya when compared to a non-steroidal anti-inflammatory drug in 
a randomised clinical trial.207 Ribavirin, on the other hand, had promising results in a small 
case series of ten patients with severe arthritis post-chikungunya infection.208 To the best of 
my knowledge, no antiviral has been evaluated in the management of chikungunya-
associated neurological disease, which therefore remains the same as that of neurological 
disease without associated chikungunya infection: for patients with encephalitis, those with a 
reduced Glasgow coma score require assessment by intensive care specialists and may 
need intubation, ventilatory support, correction of electrolyte abnormalities, management of 
raised intracranial pressure and enhancement of cerebral perfusion pressure.209 In patients 
with myelitis, corticosteroids are the standard first-line treatment, despite the lack of trial 
evidence for their use in this scenario.210 The management of GBS focuses on 
immunotherapy with intravenous immunoglobulin or plasma exchange, and ventilatory 
support if the innervation of respiratory muscles is affected.34 
 
Although not yet commercially available, it is hoped that a vaccine for chikungunya is on the 
horizon. Two phase 1 clinical trials have shown a good safety and immunogenicity profile to 
date.211,212 A recent study that tested an insect-specific alphavirus as the vaccine platform 
found promising results in mice and macaques, including immunogenicity after a single-
dose.213 
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Table 10: For the clinician – a summary.  
 
Adults and children (transmission directly via mosquito bite) 
Patients in areas endemic for chikungunya, Zika or dengue presenting with an acute neurological disorder should be investigated 
for all three arboviruses 
Encephalitis is the most commonly reported neurological complication associated with chikungunya; encephalitis has a worse 
prognosis than encephalopathy alone; a CSF pleocytosis is not always seen 
In myelitis associated with chikungunya, CSF pleocytosis and MRI changes are not always seen 
Guillain-Barré syndrome associated with chikungunya follows a similar course compared to other infections such as C.  jejuni; 
most patients recover after immunomodulatory treatment 
Disease of both the central and peripheral nervous system in the same patient can be seen in association with chikungunya 
infection 
Ophthalmological complications associated with chikungunya have been reported both at the time of infection and up to 12 
weeks after; some reports describe treating with steroids, recovery is variable  
Following chikungunya infection, complications of other organs can also occur at the same time as disease of the nervous system; 
such cases should be managed using a multidisciplinary approach 
There is currently no available antiviral treatment or vaccine for chikungunya  
Neonates (vertical transmission) 
Neonates born to mothers experiencing symptoms of chikungunya infection near the time of delivery require admission and 
observation for signs of vertical transmission for at least 7 days post-partum, as they may be asymptomatic for the first few days 
of life 
Neonates born to mothers infected outside of the peri-partum period are usually unaffected by chikungunya virus 
Caesarean section does not appear to be protective in vertical transmission of chikungunya 
Neonates infected with chikungunya should be followed up for at least 2 years, regardless of symptoms in the first week of life; 
the neurodevelopment of those without clinical encephalopathy at birth can still be affected  
 
 
3.4 Conclusion 
Neurological disease associated with chikungunya virus is being reported increasingly, in 
part due to the recent introduction of the virus to the South American population and 
associated large outbreaks. Clinicians and public health officials globally face challenges 
from the wide range of associated neurological disease and the complicating factor that 
dengue and Zika viruses are transmitted by the same mosquito vectors and have broadly 
similar epidemiology. In endemic areas, chikungunya virus should be tested for in all patients 
presenting with acute neurological disease and all mothers presenting with fever, arthralgia 
or rash; neonates with suspected symptomatic infection should be followed up for at least 
two years for evidence of neurodevelopmental delay. Future challenges include 
understanding the full scope of chikungunya neurological disease, both in neonatal and adult 
infection, and their underlying pathophysiological mechanisms. It is hoped that new direct 
therapeutic and vaccine candidates, some of which have shown promise in early studies, will 
augment the current supportive management strategies. 
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Chapter 4: General Discussion 
 
4.1 Summary 
The Zika public health emergency was recently declared over, recognising that the virus is 
here to stay and a sustained technical and research response is needed.21 Chikungunya 
virus continues to be a major concern in the tropics, with over 170,000 confirmed cases in 
Brazil in 2017 so far.104 The retrospective case series documented a wide spectrum of 
neurological complications associated with Zika virus, including central nervous system 
disease, as well as highlighting the need to be vigilant for co-infection of more than one 
arbovirus in the setting of neurological disease. Furthermore, the study showed an 
unexpected role of chikungunya virus in disease originally thought to be due to Zika. 
Following on from this, the systematic review of the neurological complications associated 
with chikungunya provides a much-needed summary of the topic. Importantly, it emphasises 
the wide range of disease, with encephalitis as the most common presentation in adults. It 
highlights that neurological complications are also sometimes seen in conjunction with 
complications of other body systems; clinicians should be aware of this, and manage such 
cases using a multidisciplinary approach. Regarding vertical transmission, the review 
underlines the need for vigilance in pregnant women infected during the peri-partum period, 
and follow-up of at least two years required for the infant, regardless of symptoms at birth. 
 
4.2 Further work done since this research 
Since the retrospective case series, further work has been done that bears significance to 
the data above. Da Silva et al. performed a prospective case series in another hospital in Rio 
de Janeiro, over a similar time period (December 2015 – May 2016) to my study.214 They 
described 35 patients with an acute neurological disorder and evidence of recent Zika 
infection. 27 patients had GBS, five had encephalitis, two had transverse myelitis and one 
had chronic inflammatory demyelinating polyneuropathy, a chronic form of GBS. The major 
limitation of this study was that chikungunya virus (circulating at the time) was not tested for, 
thus chikungunya and coinfection as the aetiology of disease in their cases could not be 
ruled out. Nonetheless, the study still adds to the evidence in favour of a wide spectrum of 
neurological disease associated with Zika virus.  
 
A simple yet intriguing epidemiological study by Oliveira et al. argues further for the potential 
role of chikungunya virus in the midst of the Zika epidemic in Brazil.215 The authors used 
routinely collected surveillance data from 2015 and 2016 to plot the number of suspected 
cases of Zika, GBS and microcephaly in the Northeast region of Brazil (see Figure 13). 
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Figure 13: Suspected cases of Zika virus infection, GBS and microcephaly in the 
Northeast region of Brazil (from de Oliveira et al., Zika Virus Infection and Associated 
Neurologic Disorders in Brazil).215 
 
As seen on the graph, both year’s increases in suspected Zika infections are associated with 
an increase in cases of GBS. However, only the 2015 suspected Zika outbreak is associated 
with ensuing microcephaly, whereas in 2016 the same pattern is not seen. The authors 
suggest three possibilities to explain this, which are not mutually exclusive: firstly, in 2016, 
the wave of suspected Zika may have in fact been due to chikungunya (which would have 
been difficult to distinguish clinically). This would explain a concomitant increased incidence 
of GBS but not microcephaly, which chikungunya does not cause; this explanation is in line 
with my retrospective work. Other possibilities raised include the potential need for an 
additional cofactor to cause microcephaly, which was present in 2015 but not in 2016; and 
that public fear of the effects of Zika in 2016 led to fewer conceptions and/or a greater 
number of terminations of pregnancy. 
 
A limitation of many of the studies investigating arbovirus-mediated neurological disease, 
and indeed in my retrospective series, is the small number of cases usually described; this is 
due to the rarity of the investigated complications and also because many affected areas 
have variable referral pathways that can lead to under-diagnosis and under-reporting. 
However, one study currently underway (led by colleagues in Recife, Brazil) that I am 
involved in the analysis of has data for over 150 arbovirus-positive cases. The study has 
retrospectively investigated patients from a single, large-volume tertiary referral centre, 
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which accepts patients from the entire state of Pernambuco, Northeast Brazil. Preliminary 
analysis of this study is in accordance with the data from Chapter 2, with a large range of 
neurological disease described secondary to Zika, as well as many patients with 
chikungunya and arbovirus co-infection. With a greater number of patients and more 
complex variability surrounding diagnostics, I looked at classifying the strength of evidence 
of the link between arbovirus infection and neurological disease for each patient into different 
groups; this was lacking in my own series. I produced a simple classification into three 
groups (for cases with a positive detection of an arbovirus), which I felt was a learning point 
as a useful tool to consider such data in a more structured fashion: 
 
Figure 14: Classification of arbovirus-positive cases depending on prodrome length 
and timing of sample collection. 
 
Key: 
I = initial symptoms of acute arbovirus infection (fever, rash, arthralgia) 
N = initial symptoms of neurological disease 
C = collection of sample for arbovirus testing 
 
In group 1, the time between initial symptoms of arbovirus infection and onset of neurological 
disease, and between the onset of neurological disease and sample collection are short. 
This gives the strongest evidence for a causal association between arbovirus and 
neurological disease. In group 2, the time between arbovirus infection and onset of 
neurological disease is longer (the 60-day cut off is arbitrary); this group of patients should 
be viewed differently. Here, might the arbovirus infection be an incidental finding and 
unrelated to the neurological disease? If the evidence for arboviral infection is a positive 
PCR test, this may indicate prolonged viral persistence, making a causal association more 
plausible. However, if it is based purely on a positive IgM antibody, which, for example, can 
persist for more than five months in chikungunya infection,216 the evidence for a causal 
association is not as strong. A caveat to this is when IgM is detected in the CSF; given IgM 
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antibodies do not cross the blood brain barrier, CSF detection of IgM implies CNS infection 
and thus causality in disorders of the nervous system. In group 3, there is an extended time 
between onset of neurological disease and sample collection. There are multiple potential 
reasons for this scenario, such as delayed presentation to hospital or samples only being 
collected at follow-up. Here, there is a risk that the patient may have had an arbovirus 
infection during this extended time, and thus a risk of attributing a causal role to an 
innocuous detected infection. Although classifying cases into the above group helps one 
assess the strength of evidence regarding a causal association between arbovirus and 
neurological disease, how can one try to mitigate such bias? 
 
4.3 Future work 
A prospective case-control study, which I have helped set up and is currently running in Rio 
de Janeiro and Recife, is designed to address some of these issues and also address other 
limitations faced in the retrospective setting. Firstly, analysing whether the proportion of 
recent arbovirus infection is statistically higher in those presenting with neurological disease 
compared with area-matched controls (without neurological disease) will clarify whether or 
not we are simply seeing an incidental finding of innocuous arbovirus infection; this will 
provide evidence for or against a causal relationship. Secondly, samples would always be 
collected at the point of admission, reducing the number of patients falling into group 3 
above. Furthermore, this would reduce the number of missing samples (of urine, serum or 
CSF) faced in my retrospective work – this would likely allow for a higher detection rate of 
arboviruses, and more complete data to differentiate between CNS and systemic infection. 
The prospective nature of such a study would also improve follow-up data, as following up 
patients in a retrospective series is more difficult logistically. Lastly, a prospective study 
recruiting all cases of acute neurological disease would help answer an important question 
that I could not answer in the retrospective series, specifically whether asymptomatic 
arbovirus infection can also cause neurological complications. This question needs to be 
addressed in order to understand the full disease burden of both Zika and chikungunya 
viruses. In addition, I recently received communication from another research team, who 
report that they have seeing a wider spectrum of neurological disease in the outpatient 
setting, such as atypical Parkinsonian syndromes and multiple sclerosis associated with 
chikungunya infection. This has not been investigated for in the retrospective study, as these 
patients do not necessarily present acutely to a hospital; future studies will need to 
incorporate this outpatient cohort. 
 
From an educational perspective, carrying out both the retrospective series and systematic 
review taught me valuable lessons for planning the prospective study, which is currently 
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underway. For example, when faced with the wide range of neurological disease associated 
with chikungunya identified in the review, I ensured that the study entry criteria allowed 
flexibility for such a range. I used strict criteria for suspected GBS, encephalopathy and 
myelopathy, but included a final criterion of “other: any other neurological syndrome (e.g. 
stroke, cranial nerve palsy, movement disorder) suspected to be linked to arbovirus 
infection.” The wording allows, for example, patients with strokes suspected to be secondary 
to arbovirus infection to be recruited, without recruiting all cases of stroke (which would far 
exceed the study’s capacity). Of note, the former criteria do not require a suspected 
arbovirus infection, in order to be able to recruit any cases that may have had a recent 
asymptomatic infection. Other lessons learnt relate to data generation, storage and analysis. 
In the retrospective study, manually entering all the retrospective data into an excel 
spreadsheet for analysis was time-consuming and inefficient; I therefore designed an online 
version of the case report form using the Research Electronic Data Capture (REDCap) 
tool.217 This has proven to be easy to use, and will greatly assist analysis of the larger 
volumes of data generated. Additionally, given the limitation of not having had all three of 
CSF, serum and urine samples for all patients experienced in the retrospective series, I was 
able to design a protocol for the prospective series that ensured all samples (and clinical 
information) needed would be acquired and clearly organised. 
 
Figure 15: Prospective study case recruitment – example protocol for sample 
collection and case-report form (CRF) section completion. 
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However, this prospective study, which started at the end of 2016, may only have limited 
relevance if Brazil does not continue to see arbovirus epidemics. Although chikungunya is 
still circulating (171,930 suspected cases this year as of September 2017), after the Zika 
epidemic of the 2015-16 summer (December-March), the country did not experience a 
similar outbreak during the 2016-17 summer, and has seen far fewer cases overall so far in 
2017 than in 2016 (15,586 suspected cases this year as of September 2017, versus 216,207 
suspected cases in 2016).104 For the prospective study, the sample size needed for an odds 
ratio of 2:1 with a low incidence of arboviral disease increases significantly, and would not be 
feasible with the current protocol. 
 
Figure 16: Suspected cases of (A) Zika and (B) chikungunya in Brazil in 2016 and 2017 
(adapted from an epidemiological bulletin from the Brazilian Ministry of Health).104 
 
A. 
  
B. 
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There are multiple reasons why dramatic outbreaks might have been seen in 2015-16 but 
not currently. One study postulated that the 2015 El Niño event may have been partially 
responsible for the scale of the outbreaks.218 The El Niño is a climatic phenomenon that 
occurs every few years, where a change in the Pacific Ocean surface temperature can lead 
to increases in rainfall and temperatures in South America; this in turn is conducive to 
greater mosquito populations and transmission of arbovirus disease. Another potential 
reason may be that a great enough proportion of the Brazilian population is now immune to 
the virus(es) after exposure in 2015-16; in effect a form of herd immunity. We do not yet 
know the seroprevalence of either chikungunya or Zika in Brazil, for differing reasons. For 
chikungunya, only two small-scale studies have investigated this, both in the state of Bahia. 
One study from a rural district sampling 120 people found a seroprevalence of 20%,219 a 
second study from the city of Salvador sampling 633 people found a seroprevalence of 
7.4%.219 More data is needed from throughout the country to further characterise this. 
Regarding Zika, although the latter study estimated its seroprevalence at 63.3%, there is 
significant cross-reactivity with dengue virus in the commercial detection kits used for 
detecting IgG-specific antibodies (Medialdea-Carrera et al., unpublished work). Given that 
the majority of the Brazilian population has been exposed to dengue, this is unreliable as a 
marker for previous Zika infection. However, I am currently involved in work using a new, in-
house inhibition assay with a Zika-specific monoclonal antibody that will hopefully overcome 
this challenge. Regardless, if the tropics do not experience further epidemics of Zika or 
chikungunya, we will need to rely on only retrospective data to further characterise their 
neurological effects. 
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Given that diagnostics proved to be challenging in the retrospective studies, with issues such 
as the possibility of serological cross-reactivity and potentially false positive PCR results, 
upgrades in existing diagnostic technologies are welcome in the field. A recent interesting 
study looked at using the CRISPR-Cas (clustered regularly interspaced short palindromic 
repeat) system in diagnostics.220,221 This is another example of optimising a cleverly adapted 
system seen in nature to scientific benefit. The researchers used Cas13a, an enzyme that is 
activated on contact with a pre-set, specific RNA sequence – on activation, the enzyme 
cleaves reporter RNA species, which fluoresce in solution, thus being able to specifically 
detect tiny concentrations of target RNA. The authors were able to use this system to 
separately identify Zika and dengue virus RNA. This technology remains to undergo clinical 
evaluation, but may hold promise with regard to improving sensitivity and specificity in the 
diagnostic workup of these patients. 
 
Further important questions will need to be addressed in future research. We currently do 
not have an accurate estimate of the rate of neurological complications as a percentage of 
all Zika infections. This may be due to firstly, the aforementioned paucity of reliable 
seroprevalence data; secondly, the need for data regarding initially asymptomatic infections; 
and thirdly, a lack of awareness amongst clinicians of the full spectrum of neurological 
disease, potentially leading to under-reporting of Zika as the cause. In a pregnant cohort of 
mothers with symptomatic Zika infection from Rio de Janeiro, Brazil, 42% (49/117) of live 
births of foetuses exposed to Zika virus in utero were found to have grossly abnormal clinical 
or radiological findings; “almost all” abnormalities affected the CNS – however, only 31 of the 
49 infants had abnormal results on clinical examination, the rest had abnormal radiology 
alone – those interpreting this imaging had knowledge of the Zika PCR status, which 
increases the risk of confirmation bias; therefore, this high result must be interpreted with 
caution.23 Another study from the USA reported a rate of birth defects of 6% (26/442) from 
pregnancies with laboratory-confirmed evidence of Zika infection; all cases had reported 
neurological disease (22 had brain abnormalities, four had encephalocele, eye or hearing 
abnormalities).222 A more recent prospective cohort study from the French territories in the 
Americas aimed to narrow down this range of 6-42% and found that of 555 fetuses and 
infants born to mothers who had preterm PCR-proven Zika infection, 39 (7.0%) had 
neurological and ocular defects possibly associated.223 Regarding adult neurological disease 
secondary to Zika, one study estimated the prevalence of Zika-associated GBS at 1.23% by 
performing a meta-analysis of three studies.224 However, the ‘denominators’ in the three 
studies, i.e. the population of Zika-infected individuals with or without neurological 
complications, were defined differently. For example, one study used PCR-confirmed Zika 
infection, whereas another included cases with clinical suspicion only. Without a 
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standardised denominator, it is difficult to draw a reliable conclusion. Regarding neurological 
complications other than GBS in Zika infection, to the best of my knowledge there is not yet 
any epidemiological evidence providing an association; this may be due to a very low 
incidence of disease or under-recognition of the potential manifestations of Zika infection. 
 
Another important area of research for both viruses is in vaccines. As mentioned in the 
systematic review, trials of chikungunya vaccines are already beginning to show 
promise.211,212 Zika, on the other hand, is more complicated. A number of studies trialling 
vaccine candidates on animal models have shown a good safety profile, induced humoral 
and cellular responses and protection from challenge with live virus.225-227 A recent phase 1 
human trial with 40 participants testing a DNA vaccine showed a good safety profile, 
induction of vaccine-specific antibodies in all cases, and neutralising antibodies in 62-95% of 
participants, depending on the cell line used.228 However, a number of issues will need 
addressing as this field develops. Firstly, in vitro studies have already demonstrated the 
ability for prior dengue infection to enhance Zika infection via the process of antibody-
dependent enhancement.106,229 All patients in our retrospective series were positive for 
dengue IgG – whether this contributed to the progression to severe neurological disease 
resulting from Zika infection is unknown. Given that a large proportion of those at risk of 
infection with Zika live in dengue-endemic areas, there is concern whether antibody 
dependent enhancement might affect the safety or immunogenicity of a vaccine 
candidate.230 Indeed very recently (December 2017), the distribution of the leading dengue 
vaccine, Dengvaxia (Sanofi), was halted in the Philippines amidst safety concerns of 
administering the vaccine to seronegative children, who may be at risk of developing more 
severe dengue disease (via antibody-dependent enhancement) should they become 
infected at a later stage.231,232 In addition, the effect on the safety of commercial vaccines for 
(or previous infections with) other flaviviruses, namely yellow fever and Japanese 
encephalitis, is unknown. Secondly, there is a theoretical possibility that a vaccine itself may 
trigger neurological disease, either via molecular mimicry or, in the case of a live attenuated 
vaccine, via direct neurotropic effects (this applies to chikungunya as well). If this were to 
occur even rarely (as reported with the yellow fever vaccine),233 it would further stress the 
importance of needing accurate data on the incidence of neurological complications seen in 
native Zika and chikungunya infection, in order to assess the value of the vaccine.  
 
4.4 Pathophysiology 
The mechanisms by which Zika and chikungunya viruses affect the nervous system have not 
been fully elucidated. Important questions include: whether the viruses act directly or 
indirectly towards neurons and if the process differs in the central and peripheral nervous 
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systems, how certain patients develop neurological disease after infection and others do not, 
the significance of the phylogenetic strain and factors driving placental transmission. Zika 
virus is a single-stranded, positive-sense RNA virus with a genome of 10,794 nucleotides, 
whose open reading frame (triplets of nucleic acid that have the potential to be translated to 
protein) codes for three structural proteins (capsid, premembrane/membrane and envelope) 
and seven non-structural proteins (NS: 1, 2A, 2B, 3, 4A, 4B and 5).7 Chikungunya virus is 
also a single-stranded, positive-sense RNA virus; its genome is approximately 12kb in length 
and has two open reading frames encoding five structural proteins (capsid and glycoproteins 
E1, E2, E3 and 6K) and four non-structural proteins (NSP: 1, 2, 3 and 4).234,235 
 
It has been shown in vitro that Zika virus can infect and affect various types of cells of the 
nervous system, including neural stem cells, oligodendrocytes, astrocytes and microglia; 
neuronal infection has been reported but appears limited.236,237 As discussed in Chapter 2, 
the para-infectious temporal profile of certain neurological presentations associated with Zika 
infection are consistent with direct neuroinvasion by the virus, leading to disease. However, 
other possibilities also exist to explain this profile, including an autoimmune process starting 
before fever-arthralgia-rash symptoms of Zika start, or a hyperacute immune response. 
Direct Zika neuroinvasion was also supported by data from a mouse model looking at 
congenital infection, where after injection of the virus into embryonic brains, it was shown to 
infect, proliferate and cause apoptosis in neural progenitor cells, causing a clinical syndrome 
of microcephaly.238 Regarding chikungunya, neurons, astrocytes and oligodendrocytes (but 
not microglia) have been shown to be susceptible to chikungunya infection in vitro; the 
former two cell types were shown to undergo apoptosis post-infection.239,240 In vivo, 
subcutaneous inoculation in macaques resulted in morphological changes in astrocytes, 
including cell body hypertrophy and alteration in the pattern of branching of their primary 
processes.241 Clearly, the in vitro and animal models have limitations with regard to 
extrapolating their data to human infection, such as route of infection and non-human cell 
types. However, they provide preliminary evidence that both viruses can potentially directly 
affect cells of the nervous system. 
 
Aside from directly affecting cells of the nervous system, much attention has been focussed 
on the role of autoimmunity in Zika and chikungunya-associated neurological disease, both 
with regard to the humoral and adaptive immune systems. Regarding the former, a study 
showed a vast range of peptide sequences on proteins expressed by both Zika virus and 
humans – many of which are associated with both congenital neurological syndromes (53 
sequences) and GBS (both demyelinating and axonal subtypes, 216 sequences).242 Thus, 
this allows for disease via a process of molecular mimicry, whereby antibodies generated 
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against a Zika peptide sequence might inadvertently affect the host’s own cells of the 
nervous system. Regarding chikungunya, the study on macaques above also found 
upregulation of toll-like receptor-2 (TLR2) in gray matter astrocytes, a gene coding for a 
sentinel cell surface receptor that plays an important role in identifying pathogens and the 
overall innate immune response.241 However, the clinical neurological state of the macaques 
was not reported, which adds to the uncertainty of whether the immune response was 
protective or pathogenic in these cases. Another study that subcutaneously inoculated mice 
with chikungunya virus detected upregulation of TLR3 in the brain, a gene that is also 
associated with the innate immune response.243 Amongst other clinical signs, these mice 
developed hind-limb paralysis, dehydration and weight loss, and 25% of them died after one 
week. However, pre-treatment with Polyinosinic: polycytidylic acid (a TLR3 agonist and 
interferon inducer), was protective clinically and promoted viral clearance from the brain, 
arguing for a protective innate immune response, at least in CNS disease. In concordance, 
faster viral clearance after chikungunya infection was seen in wild-type mice compared with 
a TLR3 knockout model; this was thought to be secondary to increased antibody neutralizing 
activity in the wild-type mice.244 Chikungunya-infected TLR3 knockout mice had increased 
viral dissemination throughout the viscera, including the brain. Along with a U-shaped 
pattern of age-specific incidence, this critical role of TLR3 is reminiscent of susceptibility to 
HSV encephalitis. Thus overall, there is evidence for both a pathogenic and protective role of 
the innate immune system in such disease, and further work is required to help tease out 
which role is more pertinent and what other viral or host factors affect them. 
 
A study from India compared the cytokine profile for patients with and without neurological 
complications following chikungunya infection.245 Of those with neurological disease, four 
had encephalitis and one had “neuropathy”. Concentrations of four cytokines (TNF-, IFN-, 
IL-6 and MIG) were found to be significantly higher in patients with neurological disease 
secondary to chikungunya, as opposed to uncomplicated chikungunya infection. These 
cytokines have a broad range of actions relating to the immune response. For example, MIG 
acts as a chemoattractant and potential stimulant of T cells.246 Again, as with the examples 
cited above for the innate immune response, it is difficult to know whether in these cases, 
such an adaptive immune response is beneficial or the actual cause of the disease. Indeed, 
in a knockout mouse model lacking mature T and B lymphocytes, the levels of chikungunya 
RNA in ankles, quadriceps muscles and spleens were elevated compared to wild type mice, 
suggesting a protective role of the adaptive immune system – however, histological 
interrogation of these organs in the acute phase showed more inflammation in the wild type 
mice, suggesting a pathological role.247 Regarding Zika, another knockout mouse study 
suggested a pathogenic role for the adaptive immune system in Zika-associated paralysis.248 
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The authors used type 1 interferon receptor knockout mice, in whom Zika virus was shown 
to heavily infect astrocytes, resulting in the breakdown of the blood brain barrier (shown by 
bright staining for mouse IgG, which is normally blocked by the barrier in mice). This, in turn, 
was accompanied by a vast infiltrate of CD8+ effector T cells associated with hindlimb 
paralysis; furthermore, CD8+ depleted mice had higher survival and only 1/9 developed 
paralysis – taken together, the results suggest a pathogenic role for these cells. Further such 
studies will need to take place in the human setting, however obvious ethical restrictions 
apply; peripheral blood mononuclear cell (PBMC) isolation will help in this scenario and 
indeed such studies are underway in the Recife cohort of patients presenting with arbovirus-
associated neurological disease. 
 
Patients diagnosed with myeloneuropathy or encephalomyeloneuropathy exhibit disease of 
both the central and peripheral nervous systems. Given the association between 
chikungunya and GBS, it is not clear whether in these cases, there is one underlying 
pathological process involving both the CNS and peripheral nerves, or dual pathology, with a 
myelopathy +/- encephalopathy centrally, and GBS peripherally. For example, a case report 
from India described a 73-year-old man who, a week after chikungunya infection, was 
admitted with drowsiness, weakness and absent reflexes, and eventually died.120 His CSF 
and MRI showed evidence of CNS involvement, and an electromyogram showed a 
sensorimotor neuropathy. A brain autopsy showed subarachnoid haemorrhage, ischaemic 
changes and small foci of demyelination without identification of viral inclusion bodies. 
Clearly, this patient had involvement of both central and peripheral nervous systems at the 
same time, but it is not clear whether the same pathological process was responsible for 
both. Elucidation of these mechanisms may help to better guide management strategies. 
 
Neurological disease secondary to chikungunya has been reported in areas with both ECSA 
(or ECSA-diverged IOL) and Asian strains, but whether these strains have differing 
neurovirulence is unknown. One study compared the effect of intracerebral inoculation of 
Asian and ECSA-diverged strains in mice.249 Both spread within the brain to a similar extent, 
but the Asian strain was associated with higher mortality than the ECSA-diverged strain. 
Upregulation of a gene associated with apoptosis was seen in the former, whilst anti-
apoptosis, antiviral and CNS protective gene upregulation were seen in the latter. This 
potentially suggests a higher neurovirulence of the Asian strain, and comparative clinical 
data from countries such as Brazil, where both strains are circulating, will be useful. 
 
On neonatal neurological disease, given that caesarean section is not protective, vertical 
transmission is unlikely to occur via the birth canal, as is the case in other neonatal 
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infections such as herpes simplex.250 Furthermore, the placenta seems to act as a barrier to 
transmission, as one study reported (as unpublished data) that placental cells from infected 
neonates were negative when labelled with anti-chikungunya antibody.61 One hypothesis 
raised by the authors is that uterine contractions result in breaches of this placental barrier, 
allowing passive passage of the virus. 
 
4.5 Conclusion 
Zika and chikungunya viruses are likely to continue to be pathogens of global concern, with 
increasing rates of urbanisation, more accessible global travel and a warming climate all 
suiting ongoing transmission via their mosquito vector. The work in this thesis helps 
document in detail the clinical range of associated neurological disease of both viruses, as 
well as highlighting other important facets, including the utility of testing multiple body fluid 
samples, issues surrounding cross-reactivity in flavivirus serology, and the phenomenon of 
arbovirus co-infection. Future work in this area should aim to provide the data required to 
answer important questions, including the rate of neurological complications in both 
arbovirus infections and the effect of prior flavivirus exposure on disease progression and 
vaccine efficacy and safety. These answers will better equip researchers, clinicians and 
public health officials to reduce the disease burden of these two arboviruses.  
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Appendix 
 
Hospitals 
Hospital Federal dos Servidores do Estado 
Hospital Universitário Pedro Ernesto 
Instituto de Pesquisa Clínica Evandro Chagas (IPEC) 
Hospital do Andaraí 
Hospital Geral de Bonsucesso 
Hospital Barra D'or 
Hospital de Clínicas de Niterói 
Hospital Bangu D'Or 
Hospital Icaraí 
Hospital Badim 
Hospital São Vicente de Paulo 
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Diagnostic criteria 
 1. Guillain-Barré syndrome (adapted from Sejvar et al. 2011, Hadden et al. 1998)251,252 
Level 1  Level 2 Level 3 Level 4 
[  ] Bilateral and flaccid weakness of the limbs 
AND 
[  ] Absence of an alternative diagnosis for weakness 
AND 
[  ] Decreased or absent deep tendon reflexes in affected 
limbs 
AND 
[  ] Monophasic illness pattern with weakness nadir between 
12 hours and 28 days, followed by clinical plateau 
 
Suspected GBS with no 
other diagnosis 
apparent, but does not 
fulfil level 3 criteria 
[  ] CSF total white cell count < 50 cells/mm3 
 OR   
[  ] If CSF results unavailable, 
electrophysiological findings consistent with 
GBS  
  
  
[  ] CSF protein level above 
laboratory normal value AND 
CSF total white cell count < 50 
cells/mm3 
AND 
 [  ] Electrophysiological findings 
consistent with GBS 
  
  Classify →   [ ] Level 1 [ ] Level 2 [ ] Level 3 [ ] Level 4 
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2. Encephalitis (adapted from Granerod et al. 2010, Venkatesan et al. 2013)141,253 
Level 1 Level 2 Level 3 
[  ] Acute or sub acute (<4 weeks) alteration in consciousness, cognition, personality or 
behaviour persisting for more than 24 hours  
[  ] Absence of an alternative diagnosis for symptoms 
[  ] New onset seizure  
OR     
[  ] New focal neurological signs   
OR 
[  ] Fever (≥ 38ºC)     
OR  
[  ] Movement disorder (includes: Parkinsonism, oromotor 
dysfunction etc.) 
OR 
[ ] EEG consistent with encephalopathy +/- epileptiform 
features 
  
[  ] CSF total white cell 
count > 5 cells/mm3 
OR 
[  ] Neuroimaging 
compatible with encephalitis 
 
  Classify →  [ ] Level 1 [ ] Level 2 [ ] Level 3 
 
 
 
 
 
 
 
 
 85 
3. Myelitis (adapted from Transverse Myelitis Consortium Working Group Criteria, 2002.)184  
Level 1  Level 2 Level 3 Diagnosis unclear 
[  ] Acute onset of weakness or sensory disturbance of upper and/or lower limbs 
[  ] Absence of an alternative diagnosis for symptoms 
[  ]  Brisk reflexes or extensor plantar response 
OR 
[  ]  Bladder or bowel dysfunction 
OR 
[  ]  Clearly defined sensory level 
  
[  ] Absence of extra-axial compressive 
aetiology by neuroimaging (MRI or CT 
myelography) 
AND 
[  ] Absence of flow voids on the surface of 
the spinal cord suggestive of 
arteriovenous malformation (MRI) 
  
  
[  ] CSF total white 
cell count > 5 
cells/mm3  
OR 
[  ]  MRI changes 
consist with myelitis 
 
Classify →[ ]Level 
1 
[ ] Level 2 [ ] Level 3 
[ ] Diagnosis 
unclear 
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4. Meningitis (adapted from McGill F, Heyderman RS, Michael BD, et al. 2016)254 
Level 1 Level 2 Level 3 
[  ] Absence of an alternative diagnosis for symptoms  
AND 
[  ] Neck stiffness   
OR 
[  ] Kernig’s sign positive (with the hip and knee at 90° angles, subsequent extension of 
the knee causes pain) 
OR 
[  ] Brudzinsky’s sign positive (involuntary lifting of the legs on lifting the patient's head 
from the examining couch) 
[  ] Fever (≥ 38ºC)   
[  ] CSF total white cell 
count > 5 cells/mm3 
OR 
[  ] Meningeal 
enhancement seen on 
contrast enhanced CT or 
MRI 
 
  Classify → [ ] Level 1 [ ] Level 2 [ ] Level 3 
 
5. Acute Disseminated Encephalomyelitis (ADEM) - adapted from the clinical definition 
proposed by Krupp, Banwell, et al., 2007255 
6. Radiculitis - based on clinical features and electrophysiological studies256 
7. Myositis - based on clinical features and electrophysiological studies 
8. Facial diplegia with paraesthesia (GBS variant) - modified from Dimachkie & Barohn, 
2013257 
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Table 1: Diagnoses of 13 patients without evidence for a recent Zika, chikungunya or 
dengue virus infection. 
 
Diagnosis Number of patients 
Guillain-Barré Syndrome 5 
Miller Fisher Syndrome 1 
Neuromyelitis optica 1 
Encephalitis 1 
Facial nerve palsy 1 
Myeloradiculitis 1 
Myelitis 1 
Encephalomyeloradiculitis 1 
Radicular pain 1 
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Table 2: Statistical analyses 
A: Wilcoxon-Mann-Whitney U-test comparing median time from infection to neurology 
between CNS and peripheral nervous system disease 
 Median time from 
infection to neurology 
(days) 
P-value 
CNS disease +/- peripheral disease 
(n=14) 
4  
0.009 
Peripheral nervous system disease only 
(n=6) 
11 
 
B: Wilcoxon-Mann-Whitney U-test comparing median time from infection to neurology 
between CNS disease (+/- peripheral disease) associated with and without CNS Zika  
 Median time from 
infection to neurology 
(days) 
P-value 
CNS disease associated with CNS Zika 
(n=5) 
1  
0.216 
CNS disease not associated with CNS 
Zika 
(n=9) 
4 
 
C: Wilcoxon-Mann-Whitney U-test comparing median time from infection to neurology 
between peripheral nervous system disease only associated with and without CNS Zika 
 Median time from 
infection to neurology 
(days) 
P-value 
Peripheral nervous sytstem disease only 
associated with CNS Zika 
(n=3) 
10 0.400 
 
Peripheral nervous system disease only 
not associated with CNS Zika 
(n=3) 
29 
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